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ABSTRACT 
Introduction. Staphylococcus aureus is the second most frequent finding in blood cultures. 
S. aureus bacteraemia (SAB) is often (in 80% of cases) complicated by deep infection. The 
invasion mechanisms of S. aureus are incompletely understood. Several pathogens can 
bind plasminogen (plg) to the bacterial cell surface receptors. Binding of plg to these 
receptors enhances activation of plg by human plasminogen activators (PAs). The 
generated proteolytic plasmin activity on the bacterial surface gives pathogens the capacity 
to invade tissues. S. aureus produces PA staphylokinase (SAK), which can activate plg to 
active   plasmin. On the S. aureus surface, the generated plasmin could turn the bacterium 
into an invasive proteolytic organism. Complicated SAB cases should be identified early to 
guide treatment decisions. The prognosis of SAB depends on the the underlying disease(s), 
immunosuppression, severity of sepsis and development of deep infection. C-reactive 
protein (CRP) is a marker of inflammation and organ dysfunction. Changes in CRP have been 
used to measure treatment response in systemic bacterial infections. Cut-off levels to guide 
treatment in SAB are unclear. Genetic factors account for up to 40% of the variation in basal 
CRP. Several single nucleotide polymorphisms (SNPs) in the CRP gene associate with 
variation of basal CRP. However, very little is known about how CRP gene SNP: s impact 
CRP levels in serious systemic infections. Serum soluble urokinase plasminogen activator 
receptor (suPAR) is a new prognostic biomarker. Elevated suPAR levels have been observed 
in malignant and infectious diseases with poor prognosis. However, suPAR has shown only 
limited value in distinguishing bacterial causes from other causes of systemic inflammatory 
response syndrome (SIRS). The studies presented here aimed to elucidate potential 
invasive mechanism of S. aureus and to evaluate the value of CRP and suPAR in predicting 
complicated disease. The following studies were undertaken: 1) to identify the effect of S. 
aureus to plg activation by SAK and to characterize plg-binding proteins 2) to evaluate CRP 
and suPAR in identifying fatal outcome and presence of deep infections in SAB 3) to assess 
the determinants of maximal CRP levels in SAB.  
Study bacteria, population and methods. In study I, clinical S. aureus isolates from Helsinki 
University Central Hospital were used in vitro. Radioactive labelling of plg was used to 
detect the binding of plg. Bacterial cell-wall proteins were isolated by affinity 
chromatography. Generation of plasmin activity was measured spectrophotometrically. 
Solubilised cell wall proteins were separated by electrophoresis and transferred to 
nitrocellulose membranes for protein blotting and visualization. N-terminal amino acid 
sequencing was performed to identify the cell wall proteins. Studies II-IV were based on 
430 prospectively followed SAB patients from a multicentre study conducted in Finland 
from 1999 to 2002. In study III, a subset of 145 patients from Helsinki University Central 
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Hospital (HUCH) was included. In study IV, suPAR levels were analysed in 59 patients from 
HUCH. They stratified according to 1-month survival and presence of deep infection to 
three groups: 1) fatalities, 2) patients with a deep infection and 3) patients without deep 
infection. In studies II-IV, CRP levels and white blood cell (WBC) counts were measured 
using standard laboratory method. In Study III, DNA was extracted by the phenol 
chloroform extraction. DNA was quantitated by measuring the absorbance. The detection 
of SNPs was performed by the analysis of primer extension products from amplified 
genomic DNA CRP gene sequencing.  
Results. S. aureus bacterial cells enhanced plg activation by SAK. Activation was not 
inhibited by alpha-2-antiplasmin (α2AP). The ability of bacteria to bind plg correlated with 
induced plasmin activity. Amino-acid sequencing revealed three tentative plg-binding 
proteins of S. aureus, inosine 5´-monophosphate dehydrogenase, alpha-enolase and 
ribonucleotide reductase. SAB patient fatalities could be distinguished from survivors by 
CRP levels already on day four. Cut-off values that predicted a 30-day fatal outcome were: 
CRP on day four >103mg/L (sensitivity 77%, specificity 55%), on day 14 CRP >61 mg/L 
(sensitivity 82%, specificity 80%) and WBC count on day 14 >8.6 x109/L (sensitivity 77%, 
specificity 78%). CRP values that predicted deep infection were: on the day of the positive 
blood culture CRP >108 mg/L (sensitivity 77%, specificity 60%) and on day 14 CRP >22 mg/L 
(sensitivity 59%, specificity 62%). Absence of CRP decline was not prognostic of mortality 
or deep infection. A deep infection was found in 84% of patients. The maximal CRP during 
the first week was significantly elevated in patients who had A-minor allele of rs3091244. 
CRP gene SNPs were analysed and they did not affect the CRP levels at the time of positive 
blood culture or seven days after. No differences were observed in predisposing factors, 
underlying diseases and clinical manifestations related to CRP gene data. The presence of 
deep infection focus and A-minor allele were both significantly associated with the maximal 
CRP level during the first week of SAB. suPAR levels on day three were higher in fatalities 
than in survivors. This difference persisted for 10 days. Deep infection was not associated 
with suPAR levels. suPAR was a prognostic marker for fatal outcome starting from day 
three, while CRP in this study setup on day three was not. 
Conclusions. Plg activation by SAK enhanced and protected against the inhibitory effect of 
α2AP when S. aureus cells or plg binding cell wall proteins were present. Three potential 
plg-binding proteins of bacterial cell surface were identified. In invasive SAB, the CRP level 
predicted both fatal outcome and presence of deep infection in the early phase of disease. 
SNPs of the CRP gene and deep infection were shown to determine the maximal CRP level 
in SAB. In SAB, serum suPAR level is a promising prognostic biomarker for fatal outcome. 
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1. INTRODUCTION 
Staphylococcus aureus belongs to the human microbiota and most commonly colonizes 
anterior nares [1]. Dissemination from colonised sites results into various clinical infections, 
ranging from superficial skin and soft-tissue infections to severe invasive S. aureus 
bacteraemia (SAB) [2,3]. The invasive nature of SAB is substantiated by the common 
associated complications, in particular deep infection foci such as pneumonia, infective 
endocarditis (IE), deep-seated abscesses, urinary tract infection (UTI), osteomyelitis or 
meningitis [3-8]. SAB is observed more often in infants, in the elderly and in patients with 
severe underlying diseases. Advanced age, comorbidities and male gender have been 
shown to increase mortality [9-11]. Mortality due to SAB remains high and, according to 
recent publications, still over 20% [12-14]. It is therefore important to find rapidly patients 
who are at greatest risk of developing complications [15]. In addition to patient related 
factors, bacterial virulence factors also impact disease development and outcome [16,17]. 
Microbe-related mechanisms may contribute to the development of superficial S. aureus 
infection into a serious invasive infection. However, these mechanisms are still 
incompletely understood [18].  
One important feature, the coagulative capacity of S. aureus, enables conversion of 
fibrinogen to fibrin. Accordingly, the coagulase test used in microbiology laboratories 
distinguishes S. aureus from other staphylococcal isolates. S. aureus secretes two 
coagulation-promoting enzymes, von Willebrand factor binding protein and coagulase, 
which both activate prothrombin non-proteolytically by forming a staphylothromin 
complex. This complex enables the protease enzyme to convert fibrinogen to fibrin [19]. In 
addition to this thrombogenic mechanism, S. aureus has the ability to digest fibrin clots. 
The majority of strains have a staphylokinase (SAK) gene and also produce the fibrinolytic 
enzyme SAK, the S. aureus plg activator enzyme [20-22]. Both of these mechanisms, 
coagulative and fibrinolytic, may facilitate bacterial pathogenesis. 
Several invasive bacteria possess plg receptors. Cell-surface bound plg is activated to 
plasmin, which converts these bacteria into proteolytic organisms capable of invasion 
[23,24]. Theoretically, SAK could be a virulence factor, which could aid bacteria in invading 
and spreading throughout the body. However, SAK production has been shown to be 
associated with less complicated bacteraemia [25] rather than a feature favouring effective 
invasion. In contrast, SAK has been proposed to be an important factor for colonization [26] 
and to have a role in controlling biofilm formation, since SAK-induced plg activation has 
been proposed to prevent biofilm formation and to induce detachment of existing biofilms 
in S. aureus infection [27].  
14 
 
A prospective clinical trial on the antibiotic therapy of SAB was conducted between January 
and May 1999 and between January and August 2003 in five Finnish university and seven 
tertiary care hospitals, and comprised 430 patients [4]. The severity of underlying diseases, 
immunosuppressive treatment, severity of sepsis and complications like deep infectious 
foci all collectively determined prognosis in these SAB patients [4,12,28]. A deep infection 
focus was found in up to 80% of patients due to meticulous searching with imaging 
techniques [29]. Later, other studies have reported relatively high occurrence of deep foci 
in SAB [14]. The radiological investigations used in deep focus visualization, such as chest 
x-ray, computed tomography (CT) scans and even radionucleotide imaging techniques are 
sometimes expensive or difficult to perform and above all expose patients to radiation [30-
32]. Therefore, biomarkers that predict the risk of development of complications might 
facilitate further investigations on the right patients at the right time [33]. 
C-reactive protein (CRP) is part of acute phase reaction and CRP levels typically rise rapidly 
in response to infection, inflammation or tissue destruction [34]. It has been widely used 
for decades in daily clinical practice in all age groups as a screening test for organic illness 
and as a sensitive indicator of disease severity and response to therapy in infections and 
inflammatory and ischaemic conditions [35-38]. In serious systemic bacterial infections, 
however, the results of studies on use of CRP in critically ill patients are not unanimous. 
One study concluded that CRP is a better marker of infection than temperature in critically 
ill patients [39], while another study claimed that CRP has only limited value in 
distinguishing sepsis from other inflammatory conditions and in predicting outcome [33]. 
In septic patients, CRP on the day of sepsis diagnosis was not a good marker of prognosis 
[40], but repeated CRP measurements were found useful on day three in predicting 
prognosis of patients with community-associated sepsis [41]. Specific studies on the use of 
CRP in predicting mortality and presence of deep infection in SAB are not available, and 
clear cut-off values might help in diagnosing patients with the most complicated disease.  
Single nucleotide polymorphism (SNP) variations of the CRP gene have been shown to 
affect the basal CRP levels in subjects without any inflammatory processes [42,43]. In 
addition, studies on associations of CRP gene SNPs with risk for many diseases are available. 
However, it is uncertain whether CRP gene SNPs as such are risk factors for diseases. CRP 
gene SNPs have been studied as tentative risk factors for ischemic stroke [44], ischemic 
heart disease [45], depression [46] and pneumonia [47]. Studies on the association of 
polymorphism in the CRP gene on CRP levels in acute inflammatory situations are limited 
to one study on by-pass surgery, in which it was observed that low CRP levels were 
associated with CRP gene SNPs [48]. 
15 
 
Urokinase plasminogen receptor (uPA) [49] is found on many cell surfaces. uPA may 
become soluble (suPAR) following cleavage and release. suPAR can be found in blood, 
serum, plasma, urine and cerebrospinal fluid. While the biological role of suPAR is unknown 
[50], as a prognostic marker it is better characterised. suPAR levels have been shown to 
correlate with fatal outcome or disease progression in cancer, human immunodeficiency 
virus (HIV), tuberculosis and malaria as well as in systemic inflammatory response 
syndrome (SIRS), type-2 diabetes, renal disease, ischemic stroke and coronary artery 
disease [51]. Even in the Danish population-based cohort study on Caucasian adults 
elevated suPAR levels were found to associate with the increased mortality [52]. Finally, 
two meta-analyses have summarised the value of suPAR in critically ill patients, and its 
prognostic value was shown to be significant [53,54].  
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2. REVIEW OF THE LITERATURE 
2.1. Staphylococcus aureus  
In 1882, Ogston described S. aureus as a cause of abscesses and bacteraemia [2], and even 
today it persists as a major pathogen causing infections in the healthy and the sick. This 
gram-positive, adaptable and dangerous bacterium belongs to the micrococcal family. In 
the laboratory, the gold pigmentation of colonies and coagulase, mannitol-fermentation, 
deoxyribonuclease and haemolysis tests distinguishes it from other staphylococci. It can be 
cultivated on regular agar plates, and tolerates transport and even drying well [55,56]. 
S. aureus produces vast amounts of different proteins [17]. The main components of cell 
wall are peptidoglycan and ribitol teichoic acid. Many other cell wall proteins bind 
covalently to peptidoglycan [57]. These cell wall proteins are immunogenic and bacteria 
protect these structures with capsule and protein A [58]. S. aureus on one hand appears to 
be a harmless commensal and on the other hand it may cause serious invasive infections. 
The bacterial pathogenetic mechanisms involved in invasive infections are only partly 
characterised [18]. In invasion, adhesion is essential as a first step and many adhesion 
molecules have been characterised, although the role of these is only partly known [59,60]. 
In addition to adhesion molecules, S. aureus produces many enzymes and other proteins 
that further aid the pathogenesis of this bacterium.  
2.1.1. Surface-associated and secreted proteins of Staphylococcus aureus 
S. aureus can express a wide array of both surface-associated and secreted proteins, which 
both play a role in virulence [17]. Altogether, there are 1354 predicted secreted proteins, 
of which only 41% have been identified. The function of less than half of these proteins is 
known [61].  
2.1.1.1 Proteins and innate immunity 
In one recent review Zecconi and Scali described S. aureus virulence-associated surface 
proteins and secreted proteins based on their role in evasion of first-line immune defence. 
This first-line immune defence (innate immunity) comprises three main components:  
? Peptides and enzymes with antimicrobial properties 
? Complement  
? Phagocytosis 
17 
 
S. aureus produces in total eight virulence factors related to evasion of antimicrobial 
peptides, e.g. SAK and aureolysin against cathelicidin and peptidoglycan O-
acetyltransferase resisting lysozyme. Seven virulence factors resist complement, of which 
SAK is one. In total, twelve other virulence factors, such as leukocidins A, B and Panton-
Valentine (PVL), have antiphagocytic properties. Finally, twenty adhesins, e.g. plasmin-
sensitive protein and fibronectin are important virulence factors [59].  
2.1.1.2. Surface-associated proteins 
In another review, Foster et al. described how surface-associated and cell wall-anchored 
proteins bound to peptidoglycan are classified into four families, based on the presence of 
motifs identified by structure-function analysis. Only eleven proteins remain structurally 
uncharacterised [60].   
? The microbial surface components recognise adhesive matrix molecules, being the 
most abundant, and include e.g. fibronectin binding proteins and clumping factors. 
? The near iron transporter motif family, comprising iron-regulated surface proteins. 
? The three-helical bundle, including only protein A. 
? Repeat domain family, comprising S. aureus protein G and plasmin sensitive 
protein. 
2.1.1.3. Toxins 
Poisonous substances produced by S. aureus are described as toxins. These toxins cause 
harm interfering with the host directly. Toxins do not include secreted surface-located 
proteins or proteins that resist host defense mechanisms inside bacteria. These toxins can 
be grouped into three categories [62]. 1) membrane-damaging toxins as receptor-
mediated, such as alpha-toxin, PVL, leukocidin A/B, leukocidin D/E and gamma toxin or 2) 
non-receptor mediated, such as α-type phenol-soluble modulins [63] and 3) toxins that 
interfere with receptor function, such as enterotoxins [64], enterotoxin-like enterotoxins 
or toxic shock syndrome toxin [62]. 
2.1.1.4. Enzymes 
By biochemical definition, many S. aureus secreted proteins are enzymes. These include 
proteases such as S. aureus serine protease A, S. aureus staphopain B cysteine protease 
and aureolysin (metalloproteinase) [62,65]. The roles of lipases and nucleases are unclear; 
however, nucleases are probably needed to degrade extracellular chromatin nets [66]. 
Coagulases staphylocoagulase and von Willebrand binding factor enable blood clotting. 
The complex formation of these coagulases with prothrombin leads to conversion of 
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fibrinogen to fibrin [67]. Fibrin clots on bacterial cells inhibit phagocytosis, favouring 
abscess formation [68], and in addition, increased adhesion to catheters [69]. S. aureus also 
produces the plasminogen (plg) activator SAK, which mediates fibrinolysis. Fibrinolysis 
mediated by SAK-activated plg has been demonstrated to lyse the fibrin network 
surrounding infection [27,70].  
2.2. Plasminogen activation in fibrinolysis and in bacterial pathogenesis 
2.2.1. Fibrinolysis and invasion of cells 
Activation of plg to plasmin is the main fibrinolytic mechanism in humans [71]. However, 
plasmin activity is also essential in physiological and pathophysiological invasion of human 
cells [72,73]. In fibrinolysis, plg is activated to plasmin by the serine proteases tissue-type 
plasminogen activator (tPA) and urokinase plasminogen activator (uPA). Endothelial cells 
produce tPA and uPA is produced by monocytes, macrophages and urinary epithelium 
[74,75]. The main activity of uPA has been observed in tissues and urine and the activity of 
tPA mainly intravascularly. Plg and plasmin are efficiently inhibited in circulation by the 
serine proteases plasminogen activator inhibitors (PAIs) 1,2 and alpha-2-antiplasmin (α2AP) 
[76]. These inhibitors control the half-life of tPA and uPA to 4-8 minutes [77]. The situation 
changes, however, when plg or plasmin binds to fibrin or to another target, and the 
inhibitory effect of plg activator inhibitors is lost locally [78].  
Taken together, in fibrinolysis plg is activated to active plasmin by two serine proteases 
[74,75]. Plasmin activity in circulation is normally inhibited by three specific inhibitors [76]. 
However, when fibrinolysis is needed to dissolve blood clots, this inhibition is lost, and local 
fibrinolysis activates [78]. 
2.2.2. Plasminogen activation in bacterial pathogenesis 
A total of sixteen invasive bacterial species have been shown to interact with the plg 
system, based on in vitro experiments [79]. The role of plg interaction is best characterised 
in experiments in vivo with three pathogens, Streptococcus pneumoniae, group B 
streptococcus [80,81], and Borrelia burgdorferi [82,83].  
Many bacteria utilise human plg activators for pathogenesis and invasion, but only three 
produce plg activators. Yersinia pestis produces pla [84,85], invasive streptococci 
streptokinase [86,87], and S. aureus SAK [20]. Bacteria may use these plg activators in 
several different ways in the pathogenesis of infection. Invasive streptococci can bind plg 
on the cell surface and then activate plg by streptokinase to plasmin [79,88]. This 
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mechanism may enable group A streptococci to penetrate pharyngeal cells [89], Group B 
and C streptococci, S. pneumoniae and S. mutans to degrade components of extracellular 
matrix and to invade host tissues [81,90,91]. Plg activation can also aid group B streptococci 
invasion of the central nervous system (CNS) and S. pneumoniae laminin degradation and 
migration through the lung epithelium [91]. Y. pestis has been shown to activate 
plasminogen by pla to facilitate in tissue-invasion [92]. Activation of plg by SAK in S. aureus 
infection has been demonstrated to promote at least local subcutaneous spreading of 
disease in skin infections [70,93]. In addition, studies have suggested a role for plg 
activation in immune evasion by group A streptococci, S. pneumoniae and S. aureus by 
complement C3/C3b degradation and for protection of group A streptococcus from 
macrophage killing [91,94-97].  
To summarize, these studies support the view that the role of plg system in the bacterial 
pathogenesis is only partly characterised. Most studies on bacterial interaction with the plg 
system are in vitro studies [79]. Three bacteria produce bacterial plg activators [20,84,86]. 
The role of these activators in the tissue-invasion and in the bacterial pathogenesis, is best 
characterised in invasive streptococci [89], and Y. pestis [92]. In S. aureus, the role of SAK 
production and plg activation in the pathogenesis is partly resolved [70,93]. 
2.2.3. Bacterial plasminogen receptors 
Plg-binding structures on the surface of many bacteria appear to be common among 
invasive pathogens. Glyceraldehyde-3-phosphate (GADH) binds plg on the surface of many 
gram-positive [98] and gram-negative bacteria [99]. Alphaenolase (α-enolase) is another 
well-characterised plg binding molecule found on both eukaryotic [100] and prokaryotic 
cells like, including streptococci [101], trichomonas [102], mycoplasma [103] and B. 
anthracis [104]. Furthermore, streptococcal M protein binds plg on streptococci [105]. 
Spirochetes, Borrelia and Leptospira also possess numerous plg receptors [79]. 
Interestingly, two of these plg receptors, GADPH and α-enolase, are both proteins better 
known as essential enzymes in glycolysis [106], which makes the presence of these 
intracellular proteins on the cell-surface even more intriguing but problematic to 
understand. Excretion of cytoplasmic proteins, however, is unlikely to result from cell lysis 
[107]. These enzymes probably have both intra- and extracellular functions representing a 
phenomenon called protein moonlightning. This protein moonlightning means that 
proteins possess many functions instead of only one. Protein moonlightning has been 
described as a single protein possessing multiple functions that are not result of splice 
variants, changes in transcription and resealing of genetic material, fusion of genes or 
consisting of many proteolytically cleaved protein fragments [108]. Recently, small 
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covalent changes in protein structure were described to partly explain protein 
moonlightning; these covalent changes were revealed to alter the biological function of 
proteins [109]. 
2.2.4. Staphylokinase  
SAK is a 15.5 kilodalton (kDa) protein and it was first described in 1948 [110] as an activator 
of plasma protease. SAK production has been detected in 58% to 85% of S. aureus strains 
[25,111]. SAK is produced in the late exponential phase of the bacterial growth cycle. SAK 
is encoded by the SAK gene, which is under accessory gene agr regulation [112]. SAK 
comprises 136 amino acids and its three-dimensional structure has been described in detail 
[113,114]. Initial plg activation by SAK has been proposed to require a tiny amount of 
plasmin [115]. In circulation and tissues, this required amount of plasmin is available due 
to spontaneous low-level turnover of plg into plasmin. SAK has been suggested to form a 
1:1 complex with plasmin, which would then non-proteolytically activate more plg to 
plasmin [115]. This activation is normally inhibited in circulation by alpha-2-antiplasmin 
(α2AP) [116]. In many studies, activation of plasminogen by SAK has been demonstrated to 
arise enhanced when components are bound in fibrin net [117] or within cell wall [118]. In 
addition, this activation has been found also to occur protected against the inhibitory effect 
of α2AP. In other bacteria, like in Y. pestis [85] and streptococci [119], secreted plg 
activators aid in invasion, but such mechanism has not been verified in S. aureus. In 
contrast, it has been suggested that plasminogen activation by staphylokinase could even 
reduce the severity of systemic S. aureus infection [120] and SAK production was even 
shown to be associated with less invasive infections in humans [93]. In other studies, SAK 
producing bacteria were demonstrated to favour enhanced subcutaneous spreading in skin 
infections [70] and to form less biofilms [27]. Finally, SAK has also been shown to interact 
with human neutrophil peptides and this interaction has been suggested to help bacteria 
at least to resist phagocytosis [121]. 
2.3. Staphylococcus aureus bacteraemia  
2.3.1. Epidemiology  
 S. aureus is the second most common pathogen in the blood cultures from bacteraemia 
patients. This has been observed in several studies and in all age groups [122-124]. The 
overall Incidence of SAB was 26.1/100 000 population in a multinational study, and no 
evidence of an increase in incidence occurred during 2000-2008 [125]. In Finland, with a 
population of 5.45 million in 2013, S. aureus caused almost 1000 bacteraemia cases 
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annually [126,127], which comprised 13% of all bloodstream infections [128]. In Denmark, 
the incidence of SAB between years 1971 and 2000 doubled (from 14 to 31/100 000 
population annually). Another study reported that the incidence of SAB had stabilised 
between 1995-2008 (23.4-21.8/100 000 population annually) [129], and that short-term 
mortality had improved from 27 % to 23 % during the study years. Increases in SAB 
incidence, hospital admissions and increases in invasive medical procedures have been 
suggested as key contributors to increases in health care-associated SAB acquisition [16]. 
Reflecting the same phenomenon, Cahill and Prendergast highlighted that wide medical 
advances [130] are associated with the increased amount of health-care associated 
endocarditis due to S. aureus [131]. In addition, the incidence of health-care associated SAB 
among haemodialysis patients is high; in worldwide studies incidence increased from over 
3 000 to almost 18 000/ 100 000 person years [132-134].  
SAB caused by methicillin-resistant S. aureus (MRSA) has remained for decades a primarily 
health care- associated infection, until community-associated MRSA epidemics emerged 
worldwide a decade ago [125,135]. However, in northern Europe the prevalence of MRSA 
has remained low [136,137]. In many countries, the high MRSA prevalence has increased 
the incidence of SAB due to MRSA. This has been shown to be an additional burden of 
disease on top of that caused by methicillin-sensitive S. aureus (MSSA) [138-140], although 
this is debatable and reports on replacement and additive effects exist [141].  
Taken together, these epidemiological reports support the view that the incidence of SAB 
is not decreasing, in Finland or world-wide. Health care-associated SAB will probably 
remain frequent because of increased amount of hospital admissions and invasive medical 
procedures. In addition, MRSA will probably continue to increase burden of SAB disease.  
2.3.2. Predisposing factors 
2.3.2.1. Colonization 
The connection between S. aureus nasal carriage and infection was first recognised in 1931 
by Danbolt [142]. S. aureus colonises the skin and mucosal membranes in up to 36% of the 
population [143,144]. Among many possible body sites, nares are the primary niche for S. 
aureus. 20% of people are persistent carriers, 30% transient carriers and 50% non-carriers 
[145,146].  Nasal carriage has been shown to be a risk factor for S. aureus infection [147], 
and it is also well recognised as a source for bacteraemia [148,149]. This is supported by 
the observation that the strains both colonizing and causing infections are often genetically 
similar [143].  
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2.3.2.2. Age and gender 
Both age and gender are shown to associate with the incidence of SAB. For unknown 
reasons, males have an approximately 1.5-fold higher SAB incidence than females 
[138,150]. The incidence of SAB is increased at both ends of the lifespan. Infants <1 years 
and people >60 years are more likely to get SAB than younger adults, and SAB incidence 
increases steadily with the increasing age [125,138,139]. 
2.3.2.3. Ethnicity 
In addition of gender and age, ethnicity is also associated with the incidence of SAB. The 
incidence of invasive MRSA infection in the African-American population is over two times 
higher than that in Caucasian Americans [151,152]. Australian aboriginals, Maori-, and 
Pacific people have an up to 20 times higher incidence than people of European origin 
[153,154]. These differences are only partly explained by socioeconomic factors [153]. 
2.3.2.4. Underlying diseases 
SAB rarely affects individuals with no underlying predisposing diseases, and many diseases 
and conditions have been associated with elevated risk for SAB. Cardiovascular diseases, 
chronic obstructive pulmonary disease, diabetes, malignancies, chronic renal failure, 
hepatic cirrhosis and HIV are all associated with an elevated risk for SAB [4,5,155-159]. 
Health-care associated SAB in HIV patients is related to low helper lymphocyte cell counts, 
and community-associated SAB with HIV positivity to intravenous drug abuse [160]. In older 
reports until the 1990s, the proportion of SAB patients with underlying diseases was high 
(>90%) [161,162]. Around the millennium, however, the situation has changed, probably 
due to increasing numbers of community-associated SAB; SAB patients have fewer 
underlying diseases than earlier [5,163,164]. 
2.3.2.5. Substance abuse 
Intravenous drug use (IDU) causes a high risk for SAB, primarily due to direct injection of 
material into bloodstream. The high SAB risk is also due to the higher rate of S. aureus skin 
colonization than the normal population [165], to frequent skin-and soft-tissue infections 
[166] and living environments where S. aureus is easily transmitted between persons [167]. 
The proportion of IDU has varied from 2% to 30% in SAB studies [159,168,169]. The 
incidence of SAB among IDUs is as high as over 600 per 100 000 person years [170]. Both 
colonization of the drug user and contaminated drugs have been identified as a source of 
bacteraemia [167,171,172].  
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Chronic alcoholism has been identified up to 15% of SAB patients [159,173]. Chronic 
alcoholism may increase both infection and SAB risk due to impaired general health, 
neglected dental hygiene and malnutrition [174]. In addition, chronic alcoholism may lead 
to compromised immunity via inhibition of neutrophil, macrophage and lung ciliary 
function [173,174].  
2.3.3. Clinical disease 
SAB diagnosis is based on positive blood culture. The clinical picture at the beginning of the 
disease is variable; the patient can present practically without symptoms or with signs of 
severe sepsis. Typically, a patient with SAB has symptoms such as chills, nausea or pain in 
the stomach, muscles or joints [3]. The most common symptom, fever, occurs in up to 96% 
of patients [168,175]. Without treatment for bacteraemia, the patient’s condition 
deteriorates and severe systemic inflammation symptoms such as hypotension, confusion 
or tachypnea may follow [176]. Studies have indicated that the most common acute 
complications such as septic shock or severe sepsis develop in 10-30% of patients 
[159,177,178] and any organ failure in 20-40% [179,180]. 
The prognosis of SAB improved at the beginning of the 1940s with the discovery of 
penicillin, which led to an increase in survival from 18% to 72% [181]. However, resistance 
to penicillin was reported in 1942, soon after its first clinical use [182]. By the 1950’s, more 
than 50% of S. aureus strains in large hospitals had developed resistance to penicillin 
[183,184]. Methicillin was developed in 1959 to overcome the penicillin resistance, but 
MRSA was already observed in 1961 [185]. The US Food and Drug Administration approved 
vancomycin in 1958 [186]; resistance to vancomycin has taken four decades to develop. 
During the period of modern antibiotics (1950-1980) mortality due to SAB has varied in 
different studies from 25 to 50% [187-189]. Before the millennium, prognosis was possibly 
improved and reported mortality fell to almost 20%. During last two decades, reported 
mortality has been 14-30% in both health care-associated and community-associated SAB 
[190-192]. 
2.3.4. Prognostic factors 
Prognostic factors for mortality due to SAB consist of patient-related and clinical disease 
related factors. Prognostic factors with reported odds ratios are shown in Table 1. Other 
reported prognostic factors include hyperbilirubinaemia [189], thrombocytopenia [193], 
neutropenia [10], persisting bacteraemia [169] and acute renal failure [159]. Contrasting 
results of the prognostic significance of MRSA have been reported. Several studies have 
not been able to detect a difference in mortality between patients with SAB due to MRSA 
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or MSSA [194-198]. In some studies health care-associated origin of SAB has not impacted 
to mortality [6,164,168,199,200], while in one study mortality due to health care-
associated SAB has been lower compared to mortality due to community-associated SAB 
[159].  
Table 1.  Prognostic factors with reported odds ratios for mortality due to Staphylococcus 
aureus bacteraemia. MRSA=methicillin-resistant S. aureus. MSSA=methicillin-sensitive S. 
aureus. OR= significant odds ratios for prognostic factors. 
Prognostic factor OR reference 
Age >65 years 1.6-2.3 [10,138,164,194,201] 
Ultimately or rapidly fatal underlying diseases 2.7 [9] 
Ultimately fatal underlying disease 1.02 [195] 
Rapidly fatal underlying disease 3.38 [195] 
Severe sepsis or septic shock 2.68-25.7 [159,199,202,203] 
Delayed empiric antibiotic 2.15-3.8 [204,205] 
SAB due to MRSA  1.69-2.6 [164,169,177,206,207] 
Uneradicated infection focus 4.17 [196] 
Deep infection focus:   
    Pneumonia 5.8-6.46 [6,194] 
    Endocarditis 2.8-12.13 [207,208] 
    Meningitis 21.4 [8] 
Unknown infection focus 4.1-8.67 [194,209-211] 
Stroke associated with endocarditis 2.5-32 [212-214] 
Health care-associated SAB 1.42-1.75 [10,215] 
 
2.3.4.1. Underlying diseases 
In the 1960’s, McCabe and Jackson created a widely-used classification system for 
categorising underlying diseases of patients to: healthy, non-fatal, ultimately- and rapidly 
fatal [216]. This classification has been successfully used in many studies, because it 
independently predicts fatal outcome [195,217-219]. In SAB studies, the risk of death was 
shown to increase incrementally among its three categories [195,219]. Underlying diseases 
associated with higher mortality in SAB include alcoholism [159], immunosuppression 
[159], diabetes [194], liver cirrhosis [9,10], cardiac disease [6,220], malignancies [9,221], 
renal failure and dialysis [10,159] and the presence of multiple comorbidities [5,222]. 
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2.3.4.2. Severity of illness 
The severity of illness is one of the established predictors of 30-day mortality in SAB [192]. 
Severe sepsis and septic shock in SAB is associated with a high overall mortality rate 
(between 40-80%) [192,200,203,223]. Severity of illness can be evaluated with different 
severity-of-disease scores, primarily used in intensive care units (ICU). These scores 
include: 
? The Acute Physiological and Chronic Health Evaluation II (APACHE II), is designed 
to assess the severity of illness. In APACHE II score, severity of illness is utilised in 
addition to previous health status (including chronic illnesses) for patients 
admitted to ICUs [224]. 
 
? The sequential organ failure assessment score (SOFA) means that, on assessment 
of respiratory, cardiovascular, coagulative, hepatic, renal and neurological 
functions, SOFA points on a scale of 0-4 are given to each function [225].  
 
? The Pitt bacteraemia score (Pitt-score), is a scoring system that predicts mortality 
due to sepsis in ICUs. Required clinical parameters are fever, presence of 
hypotension, need for mechanical ventilation, cardiac arrest and altered mental 
status [226].  
 
? The multiple organ dysfunction score (MODS) uses simplified measures of 
physiological dysfunction in several organ systems with strong correlation to fatal 
outcome in ICU-treated patients [227].  
These severity of disease scores have all predicted mortality in bacteraemia due to S. 
aureus [6,218,222,228,229].  
Specific conditions associated with higher risk for fatal outcome in SAB include altered 
mental status [230], need for mechanical ventilation [201] or ICU treatment and SAB 
occurring during ICU treatment [195,203,222]. 
2.3.4.3. Infection focus  
Infection focus in SAB is important to identify because it can affect prognosis and the length 
of antibiotic treatment [231]. However, variable definitions of infection foci in the literature 
make comparison of different patient materials challenging. Studies on SAB have used 
three different classifications to describe the level of infection focus: 1) primary or 
secondary, 2) complicated or uncomplicated or 3) cutaneous or deep focus. Nolan 
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categorised infection foci as primary or secondary [232]. Primary foci included skin and 
soft-tissue infections [3,233,234], indwelling intravascular devices [162], pneumonia [235-
237], urinary tract infection (UTI) [238,239], and unknown portal of entry [162,169]. 
Secondary infection foci are sometimes challenging to categorise strictly. However, clearly 
secondary infection foci are IE, deep-seated abscesses, meningitis (unless postoperative), 
septic arthritis without local trauma or surgery [155,194,232,240], and usually UTI if the 
same S. aureus strain causes both bacteraemia and UTI [162,241]. Pneumonia can be either 
a primary focus [235,236] as a result of aspiration or a secondary focus due to septic emboli 
from an infected tricuspid valve [240]. The presence of secondary infection focus, 
recurrence of SAB within three months, shock, acidosis, acute respiratory distress 
syndrome, disseminated intravascular coagulopathy, CNS involvement and evidence of 
autoimmune or embolic events have been definitions for complicated SAB [162,241-243]. 
Tan and File created a practical classification for infection foci. They categorised S. aureus 
infections as cutaneous and deep, which included bacteraemia, osteomyelitis, septic 
arthritis, deep-seated abscess, endocarditis, pneumonia, and foreign body or CNS infection 
[244]. The same kind of deep infection focus classification as Tan and File created, was used 
by our study group in previous articles [28]. 
2.4. Biomarkers and diagnosis of deep infection focus 
Published data on use of erythrocyte sedimentation rate (ESR), white blood cell (WBC) 
count and CRP in predicting the presence of a deep infection focus in SAB is limited. 
Reported studies on the use of CRP in predicting deep infection focus other than IE, 
pneumonia, or surgery-related infections in SAB are not available. 
 In studies on predicting surgery-related infections but not specifying the causative 
microbes, high CRP but not elevated WBC count predicted (postoperative day two) 
development of a postoperative infection (median nine days postoperative) in patients 
who had underwent cardiac surgery [245]. In another study, both elevated CRP level and 
WBC count were found to be good markers for postoperative complications [246]. CRP 
>100 mg/L on postoperative day four was found predictive for infection in patients who 
had underwent post-lumbar instrumentation surgery, whereas greater elevation of 
leukocytes at day seven as compared to day four was not [247]. 
ESR is defined as the distance that a vertical column of anticoagulated blood has fallen in 
one hour. Although there have been many studies on the clinical use of ESR in the last 
several decades, its value and specificity in diagnosing any infections is still unclear [248]. 
Sensitivity was low (0.36) among patients with infection in general but specificity was high 
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(0.97) [249]. ESR is moderately raised in hip prosthesis infection. It is useful in diagnostics, 
since symptoms, X-rays or scans do not distinguish infection from loosening. 25% of these 
infections were shown to be caused by S. aureus [250]. Elevated ESR and leukocytosis were 
published to be markers of spinal bacterial abscess, but the causative microbes in this study 
were not specified [251]. In evaluating low-grade bone infection, ESR was found to have 
value [252]. However, when ESR was compared to CRP, ESR had lower sensitivity than the 
CRP acute-phase response [253]. 
A review article on emergency department use of biomarkers in diagnosing osteomyelitis 
concluded, that in patients with low-level suspicion of osteomyelitis, age-adjusted normal 
ESR and CRP <5 mg/L could be used to exclude osteomyelitis. However, in case the clinical 
suspicion is very strong, normal values should not be used to rule out the diagnosis. In 
addition, in this same article it was mentioned that WBC count is not helpful in diagnosing 
osteomyelitis [254]. In addition, one meta-analysis concluded that CRP appeared to have 
only limited value in diagnosing osteomyelitis and septic arthritis [255].  
2.5. Deep infection focus in Staphylococcus aureus bacteraemia  
2.5.1. Infective endocarditis 
Currently, S. aureus is the most common causative microbe of IE in high-income countries, 
with a proportion of almost 30% [207,256]. The epidemiology of IE has changed radically in 
high-income countries. The major risk factor for IE, was earlier rheumatic heart disease, 
but it has been replaced by risk factors such as degenerative valve disease, diabetes, 
cancer, intravenous drug use, and congenital heart disease [131]. Rheumatic disease as a 
consequence of streptococcal pharyngitis is currently uncommon disease these days due 
to good availability of antibiotics and improved living standards [257]. Despite of these 
improvements, the incidence of IE has not decreased and is still 3-10/ per 100 000 people 
[256,258]. It was emphasised that the increased amount of staphylococcal IE could be a 
result of medical progress [259]. In hospitalised patients, the presence of long-term central 
venous catheter (CVC) and invasive procedures are known risk factors for SAB and in 
practice for IE [191,260]. In addition, extensive use of implemented material, indwelling 
catheters, pacemakers and prosthetic valves were all reported to increase risk of SAB and 
IE [261,262].   
S. aureus IE is usually acute and causes high fever in up to 90% of patients, often with no 
physical finding. When medical help is sought (on average in three days) [191,263] ), heart 
murmur can be heard in 90% of patients [264]. On admission, physical signs of peripheral 
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embolism include petechia or Janeway lesions; splenomegaly is occasionally seen [131]. IE 
may progress and local complications, such as myocardium and valve ring abscesses, and 
purulent pericarditis, might develop. In addition, extracardiac metastatic infections, such 
as vertebral osteomyelitis and peripheral abscesses are common [3].  
Systemic septic thromboembolic complications occur in 25-50% of patients [234,265], 
mostly in left-sided IE, affecting the spleen, kidney, liver and CNS. Large vegetation (>10 
mm) and IE in the mitral position are associated with elevated risk for embolization 
[234,265]. Less common right-sided IE (in 5-10% of patients) usually affects the tricuspid 
valve, which may cause respiratory symptoms as a result of pulmonary embolism together 
with signs of sepsis [266]. 
S. aureus prosthetic valve IE carries a poor prognosis (1-year mortality is >50%). One third 
of all cases are health-care-associated [267], and overall risk was found independent of 
valve position and material used [268,269]. S. aureus is a frequent cause of prosthetic valve 
IE occurring within 1-year after surgery. However, after this period the causative 
microorganisms were the same as those causing native valve IE [3].  
Prevalence of IE in SAB has been 10-13% [169,270,271]. Echocardiography is indicated in 
most cases. Transthoracic echocardiography (TTE) is readily available and non-invasive. 
However, the sensitivity of TTE in diagnosing valvular IE is low (30-60%) [272,273].  
However, a normal TTE was shown to rule out IE in health-care associated SAB, in high-risk 
cardiac conditions and in IDUs. Normal TTE might be acceptable to rule out IE in these SAB 
patients [274]. Transesophageal echocardiography (TEE) is more accurate and sensitive 
than TTE in visualising cardiac structures. In native valve IE, the sensitivity of TEE (95%) was 
higher compared to TTE (55%) [275,275,276].  
2.5.2. Pneumonia 
S. aureus is an uncommon (prevalence 1-11%) cause of community-associated pneumonia 
[277-279]. However, S. aureus causes one third of health-care associated pneumonia cases 
[235,236]. In health-care associated pneumonia, S. aureus first colonises mucous 
membranes followed by aspiration, which causes pneumonia. In general, pneumonia 
occurs in SAB in 6-34% of patients, and it may result from tricuspid valve endocarditis or 
septic pulmonary emboli. In addition, abscesses and empyema may also complicate 
pneumonia [155,157,280]. Community-associated pneumonia due to PVL toxin-producing 
S. aureus has emerged globally and causes necrotising, and often (in 56-63% of patients) 
fatal disease [135,281]. Chest X-ray to diagnose pneumonia has long been a fundamental 
diagnostic tool based on international recommendations [30]. Recently, lung 
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ultrasonography has been proposed to be even the first-line examination instead of chest 
X-ray [282]. Chest CT-scan has been the gold standard in diagnosing pneumonia due to its 
close to 100% sensitivity and specificity in diagnosing pneumonia [31]. However, its 
indications are limited due to ionization radiation exposure and availability. In diagnosing 
rare SAB related condition, septic pulmonary embolism, a CT-scan has been shown to be 
confirmative of diagnosis [283] 
2.5.3. Deep-seated abscess  
In earlier studies, the frequency of deep-seated abscesses (between 1-24%) 
[175,191,194,199,201,270,284] and its definition have varied. The variability is likely due 
to different definitions used in these studies. Infection was defined as superficial or deep 
[244]. Some studies included only psoas abscesses [191], while others only epidural 
abscesses [175,199] or abdominal abscesses [284].  
2.5.4. Septic arthritis and osteomyelitis 
S. aureus is the most common causative bacteria in septic arthritis, causing half of all cases 
[285,286]. Known risk factors are rheumatoid arthritis or osteoarthritis, joint prosthesis, 
low socioeconomic status, IDU, alcoholism, diabetes, previous intra-articular corticosteroid 
injection and cutaneous ulcer [287]. The frequency of septic arthritis in SAB varies from 1% 
to 24% [4,285,288]. Septic arthritis can be of non-haematogenous origin (caused by local 
injury or trauma) or iatrogenic (related to surgical-procedure), the latter origin being more 
frequent than the former [240,289]. Septic arthritis typically affects a single joint, most 
often the knee, the second most often the hip and the shoulder. The other joints are 
seldom involved, although any joint can be affected [290].  
S. aureus is the primary pathogen in over half osteomyelitis cases [291]. The disease 
originates from haematogenous seeding, contiguous infection or is related to vascular 
insufficiency [292]. Vertebral column osteomyelitis commonly affects the intervertebral 
disc and surrounding soft tissues [293]. Bacteraemia may originate from another primary 
source, which then creates a secondary focus, spondylodiscitis, which serves as a 
continuous source of bacteraemia. Staphylococcal spondylodiscitis was found in 7% of 134 
cases of bacteraemia by the ward physician and in 13% of 100 cases investigated by an 
infectious diseases specialist [294]. A Danish report concluded that 82% of spondylitis cases 
were due to SAB [295]. 
Radiographs are the initial imaging studies performed when bone and joint infections are 
suspected; the sensitivity and specificity are 50- 75% and 75 - 83%, respectively. CT and 
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ultrasonography are not considered to be the primary imaging modalities for osteomyelitis. 
With magnetic resonance imaging (MRI), the earliest findings of osteomyelitis can be 
detected after two days in osteomyelitis. MRI also has a very good negative predictive value 
in ruling out osteomyelitis [283]. In addition, the use of modern techniques utilising 
radionucleotides has increased in diagnostics of patients suspected of difficult to diagnose 
musculoskeletal infections. Bone 67-Gallium imaging has diminishing importance due to 
more appropriate procedures, such as labelled leukocyte imaging and, in case of spinal 
infections, 18F-fluorodeoxyglucose (18F-FDG) imaging. Single-positron emission computed 
tomography/computed tomography (SPECT/CT) and positron emission 
tomography/computed tomography (PET/CT) have shown improved accuracy in the 
diagnostics of patients with suspected musculoskeletal infections [32]. 
2.5.5. Meningitis 
S. aureus is unusual causative microbe of meningitis. Worldwide, it constitutes 0.3-8.8% of 
all cases of bacterial meningitis [296-298]. Mortality varies between 14-77%. Meningitis 
associated with SAB has a poorer prognosis than health care-associated S. aureus 
meningitis without SAB. Health care-associated S. aureus meniningitis are associated with 
neurosurgical procedures, cerebrospinal fluid shunt device placement or trauma [299-301]. 
2.6. Treatment of Staphylococcus aureus bacteraemia 
The study subjects of this thesis do not address treatment of SAB. In brief, the standard 
treatment of SAB in countries with low MRSA prevalence, including Finland, is 
semisynthetic penicillin (cloxacillin) [4]. First-or second generation cephalosporins and 
clindamycin can be used, if the patient has a non-anaphylactic allergy to penicillin 
antibiotics [302]. Bacteriostatic clindamycin has good bone penetration; however, 
clindamycin is not recommended for treatment of endocarditis [157,303]. Vancomycin is 
used for treatment of MRSA SAB and for patients intolerant for beta lactam antibiotics 
[304,305]. The duration of parenteral therapy in uncomplicated SAB, typically central 
catheter related, is recommended to be 14 days [306,307]. Longer therapy durations (up 
to 4-6 six weeks) are recommended in patients with a deep infection focus, especially left-
side endocarditis [3,308,309]. In a recent meta-analysis, rifampicin adjunctive therapy was 
shown to associate with trends towards reduced all-cause mortality and reduced clinical or 
bacteriological failure [310]. Rifampicin combination therapy may be associated with 
improved outcome in patients with a deep infection focus [311]. 
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2.7. Biomarkers of infection 
2.7.1. C-reactive protein (CRP) 
In 1930, Tillet and Francis found C-reactive protein in the sera of pneumonia patients [312]. 
Later, it was shown that CRP production was not limited to streptococcal pneumonia but 
could also be detected in a variety of acute bacterial infections, including staphylococcal 
osteomyelitis, rheumatic fever, subacute bacterial endocarditis and lung abscesses [313-
315].  
2.7.1.1. Biological function of CRP 
The discovery of CRP led to the identification of many other molecules whose production 
is enhanced in inflammatory processes; these proteins are collectively called acute-phase 
proteins. The expression, structure and function of CRP, the major acute phase protein, has 
since been solved, as reviewed [316]. CRP is known to have calcium -dependent specific 
binding to phosphocholine (PCh), an important component of most cell membranes, 
including bacterial and fungal polysaccharides. PCh is thought to be the most important 
ligand of CRP and responsible for major biological functions. The reason for this is believed 
to be its wide distribution in many pathogens and in necrotic and damaged eukaryotic cells 
[316]. In addition, ligand-complexed CRP can also activate the classical pathway of human 
complement [317] and recruit phagocytic cells [318,319]. These functions, namely the 
ability to activate complement and to facilitate phagocytosis, place CRP as an integral 
element of the innate immunity [316].  
2.7.1.2. Synthesis of CRP 
The liver is the primarily source of CRP production during the acute-phase response to 
cytokines released by macrophages and adipocytes. A large (even up 1000-fold) and rapid 
increase in CRP concentration within 24-48 hours, followed by an equally rapid decrease 
are characteristics for CRP. The circulating CRP concentration is determined by the 
synthesis rate, and CRP production directly reflects the strength of the inflammatory 
process stimulating it [320]. The main inducer of the CRP gene is interleukin 6 (IL-6), while 
interleukin 1 (IL-1), complement-activated products and glucocorticoids augment the 
effect of IL-6 [316,317,319].  
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2.7.1.3. CRP gene 
The human CRP gene is located in the first chromosome between 1q21 and 1q23 and 
consists of 2 exons and 1 intron. CRP expression is regulated mainly at the transcriptional 
level by IL-6, while IL-1, complement and glucocorticoids enhance its effect [321,322]. 
Factors associated with genes account for up to 40% of the basal CRP level variations; more 
than 100 single nucleotide polymorphisms (SNPs) residing in the noncoding regions around 
the CRP gene have been characterised [42,43]. In addition, SNPs in the genes of CRP 
promoters e.g. IL1 and IL-6 have been shown to impact basal CRP variation [323]. In 
addition, CRP gene SNPs tentatively associate e.g. with the risk of diabetes [324], ischaemic 
stroke [325,326], reduced arterial compliance [327], cognitive decline after cardiac surgery 
[328], ischaemic heart disease [329,330] and susceptibility to infections [327,331].  
Seven SNPs across the CRP gene in survey have been identified as functional [332]. SNPs 
within the CRP gene were genotyped in large American general population cohort. This 
study revealed that two SNPs rs3093058 and rs3091244 were associated with increased 
baseline levels of serum CRP. Two other SNPs rs1205 and rs2808630 were associated with 
decreased levels of baseline serum CRP [333]. Six bin tag SNPs association with CRP levels 
was studied in another large study. Study indicated highly significant association of SNPs 
rs3093059 and rs3091244 with baseline CRP levels [334]. Triallelic SNP rs3091244 is within 
promoter region of the gene and it is functionally most important, both rare T and A alleles 
associate with high CRP levels [332-334]. In addition, tentative associations of this 
functionally important SNP with many diseases have been studied extensively. In all studies 
shown in Table 2 elevated baseline CRP levels were shown to associate with minor A-allele 
carriage. 
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Table 2. Association observed between the CRP gene SNP rs3091244 A-minor allele with 
diseases.  Association = +, lack of association = - 
 Disease  +/- Reference 
 Metabolic syndrome  + [335,336] 
Reduced carotid artery elasticity + [337] 
Fatigue in breast cancer patients - [338] 
Increased prevalence of coronary artery disease - [339] 
Elevated activity of ankylosing spondylitis (AS) + [340] 
Risk for developing AS + [341] 
Low dispositional optimism (only in obesity)  + [342] 
Ischaemic stroke + [343] 
Abdominal aortic aneurysm (AAA) and greater AAA diameter + [344] 
Tumorigenesis especially in rectal cancer + [345] 
2.7.1.4. High-sensitivity CRP 
High-sensitivity CRP (hs-CRP) assays measures CRP in the low range, from 0.5- mg/L to 10 
mg/L [346]. Compared to standard CRP, hs-CRP can detect more precisely baseline CRP 
levels. Baseline CRP elevations may indicate low but persistent inflammation [347]. CRP 
elevations over 2 mg/L are associated with “metabolic inflammatory” states, including 
cardiac ischaemia, smoking, and other low level non-infectious inflammatory conditions 
such as uraemia [347,348]. Elevated baseline CRP levels were also associated with an 
increased risk for lung cancer, and possibly breast, ovarian and colorectal cancers [349]. 
2.7.1.5. CRP and infectious diseases 
Elevated CRP levels generally indicate infection, inflammation or trauma. It is not a specific 
diagnostic marker for diagnosing infection in these conditions and between-patient 
variation in CRP levels can be remarkable in seemingly similar conditions [36]. Rather, CRP 
should be used to monitor disease progression in individual patients.  Pneumonia and UTIs 
are among the most frequent diseases in the general population, and CRP may be useful in 
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assessing severity or a possible bacterial cause. In severe life-threatening conditions, such 
as meningitis, CRP is used to differentiate bacterial infection from viral [37,39]. Although a 
viral infection such as influenza can elevate CRP to a relatively high level, an extremely high 
CRP elevation (>500 mg/L) was shown to associate with an over 80% likelihood of bacterial 
infection [350]. The usefulness of CRP in following SAB has not been studied but there is 
data on its use in other severe bacterial infections. 
 2.7.1.6. CRP in pneumonia 
In community-associated-pneumonia, CRP was shown to be an independent predictor of 
disease severity [351,352]. However, the use of CRP use as a prognostic marker in 
pneumonia has also been questioned [353,354]. While the role of CRP as a prognostic 
marker in pneumonia seems to be unclear, it can be useful in distinguishing between 
bacterial and viral respiratory tract infections. In lower respiratory tract infections, it has 
been suggested that CRP could be used to assess the need for antibiotics:  CRP level <20 
mg/L no antibiotics usually needed, 21-50 mg/L no antibiotics in most cases, 51-99 mg/L 
antibiotics in most cases and >100 mg/L prescribing antibiotics is usually needed [355,356]. 
Thus, in accordance, with a narrative-review of primary care point-of-care testing, CRP was 
shown to distinguish relatively well whether patients with respiratory tract infection 
needed antibiotics or not [357]. However, in the very acute initial phase of the disease (e.g. 
streptococcal sepsis) CRP level should be interpreted with caution. In patients with a very 
acute disease onset, CRP levels may be at low-level at presentation due to slow kinetics of 
CRP [320]. 
2.7.1.7. CRP in infective endocarditis 
In patients, who had undergone a cardiac operation, CRP level elevations were reported in 
all patients postoperatively and peak values were reached at 72 hours after the operation. 
In addition, a progressive decline in CRP levels was seen in those without postoperative 
infection. The difference in CRP levels between patients with infection (including patients 
with prosthetic valve IE) and those without were significant and of prognostic value in 
evaluating the response to therapy and in predicting outcome [358]. Serial CRP 
measurements as a predictor of IE outcome were evaluated in a study. In this study 19.5% 
of all patients had S. aureus IE. The adjusted OR for poor outcome at one week was 10.3 
(95% confidence interval, OR 2.2-49.4) for patients with CRP levels in the highest tertile 
(>122 mg/L) vs. the lowest tertile (1-69 mg/L). In addition, a slow percentage decline in CRP 
level in the first week indicated poor clinical outcome [359]. In an IE study 32% of patients 
had S. aureus IE. In this study, CRP levels measured on admission were evaluated in 
predicting poor clinical outcome. The primary endpoint, poor clinical outcome, was defined 
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as death or serious complications occurring during the hospital stay. Infectious 
complications comprised of septic arthritis, osteomyelitis, meningitis, visceral abscess, 
mycotic aneurysm, peripheral emboli, septic pulmonary infarction and intracranial 
infarction or haemorrhage. The study showed that on admission, CRP levels were 
significantly higher in patients with poor clinical outcome than patients who survived and 
did not develop serious complications during hospitalisation. [360]. Later, one more study 
including also S. aureus IE patients showed, that increasing preoperative CRP reliably 
predicted poor outcome in surgically treated IE patients (OR 18.15, 95% CI: 1.5-223.60) 
[361]. 
In diagnosing IE, elevated CRP values have been shown to correlate with the presence of IE 
with mixed etiologies, [362-364], and a normal CRP was useful in excluding IE [365]. In a 
study, which compared patients with bacteraemia of mixed aetiologies, including S. aureus, 
it was found out that both procalcitonin (PCT) and CRP were not significant in 
differentiating patients with IE from those with bacteraemia only [366]. In diagnosing IE, 
the value of CRP was later evaluated in a meta-analysis, (based on 6 studies). This analysis 
did not support the use of CRP to rule out IE [367]. Finally, in a recent study evaluating the 
diagnosis of lead-dependent IE, the second most common causative microbe was S. aureus, 
and CRP levels were found to have a significant relationship with possible lead-dependent 
IE [368]. 
2.7.1.8. CRP in urinary tract infection 
CRP may assist a clinician in differential diagnosis between cystitis and pyelonephritis. Clear 
cut-off values, however, are not so well established. Sandberg et al. studied women with 
symptomatic UTI and found CRP >30 mg/L to confirm the diagnosis of pyelonephritis in 94% 
of non-pregnant patients, in 91% of pregnant patients. In patients with cystitis, 5% had CRP 
above this limit [369]. In a large study on patients on rapid diagnostics of UTI, good 
concordance of CRP with clinical pyelonephritis diagnosis was observed [370]. Consistent 
with these studies, Agrawal et al. observed that in adult patients (>16 years) the mean CRP 
was significantly higher in patients with UTI infection as compared to controls [371]. In a 
Korean study on febrile UTI with 325 patients, bacteraemia was detected in 106 patients. 
Bacteraemic patients had a higher mean CRP than patients with negative blood cultures. 
However, in multivariate analysis, CRP was not associated with bacteraemia [372]. In 
detecting fatal outcome, CRP was not prognostic for 30-day mortality in febrile UTI patients 
[373], but was prognostic for mortality in pyelonephritis patients with emergency 
nephrectomy due to infection [374]. The diagnostic value of leukocytosis, CRP, pyuria, urine 
cultures and duration of time before arrival to hospital in detecting kidney abscess were 
evaluated in 213 patients who underwent CT scan. 50 patients were found to have an 
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abscess, nevertheless, not any risk factor or diagnostic parameter, including CRP, could 
predict the presence of an abscess [375].  
2.7.1.9. CRP in meningitis 
In bacterial meningitis, the serum CRP level is typically elevated while in viral meningitis it 
is usually low [376-379]. CRP has been shown to have a good diagnostic accuracy in 
distinguishing bacterial meningitis from viral meningitis if used as an adjunct to lumbar 
puncture [380]. A cut-off value of >50 mg/L was proposed for adults combined with 
cerebrospinal fluid pleocytosis. For children under 6 years, a cut-off value of >20 mg/L was 
proposed to distinguish bacterial from viral meningitis. However, the accuracy was low in 
patients with symptoms less than 12 h [377]. CRP levels were observed to be higher in 
bacterial meningitis than aseptic meningitis in a small study of 32 patients [379].  
2.7.2. White blood cell count 
The white blood cell (WBC) count is frequently measured biomarker in many infections. In 
recent review, Honda and Takayuki described use of WBC count and neutrophil left shift as 
markers of bacterial infection. Neutrophil left shift means that there are more than usually 
immature forms of neutrophils in the blood. In bacterial infection leukocytes are consumed 
in large amounts and WBC count reflects both consumption and production of neutrophils 
in the blood marrow. Unchanged WBC count means that consumption and production are 
in balance. During bacterial infection changes in WBC count are dynamic and reflect the 
seriousness of bacterial infection [381].  
Up to fifth of all patients had no leukocytosis in bacteraemic pneumococcal pneumonia at 
presentation [382]. WBC counts showed no differences between groups of patients who 
had either bacterial, viral or mixed viral-bacterial pneumonia [383]. In diagnosing upper 
UTI, blood WBC count is usually not needed for diagnosis. However, in predicting UTI in 
urolithiasis patients, blood WBC count was significantly different between urine culture 
negative and positive patients [384]. Whereas WBC count was not significantly different 
between patients with urosepsis, severe urosepsis and uroseptic shock following 
percutaneous nephrolithotomy [385]. WBC count was significantly prognostic and 
diagnostic biomarker for infection and combination of WBC count and PCT had better 
diagnostic and prognostic value for infection than PCT alone in ICU patients [386]. WBC 
counts measured on admission were significantly higher in patients with poor clinical 
outcome than patients who survived and did not develop serious complications during 
hospitalisation in an IE study [360]. WBC count was reported as prognostic also in initially 
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healthy individuals. Leucocytosis (>9.0 leukocytes/ml) was a significant predictor in 
Normative Aging Study population for increased future mortality in men [387].  
To summarize, these studies support the view that WBC count in pneumonia is a diagnostic 
supplement at most [382,383]. Blood WBC count can be useful in urolithiasis [384,385], but 
blood WBC count is normally not needed in diagnosis of upper UTI. Furthermore, WBC 
count is useful or at least additive to other biomarkers in predicting infection or prognosis 
in ICU patients [386]. Leukocytosis could also be future prognostic marker in healthy men 
[387].  
2.8. Other potential biomarkers in Staphylococcus aureus bacteraemia  
2.8.1. Soluble urokinase plasminogen activator (suPAR) 
suPAR has been reported as a promising prognostic marker. Poor outcome and disease 
progression in cancer, HIV, tuberculosis, malaria, SIRS, diabetes, renal disease, ischemic 
stroke and coronary artery disease correlated with elevated suPAR levels [51]. The 
urokinase plg activator receptor, a well-described versatile protein [49], is found on many 
cell surfaces and soluble suPAR can be detected in blood, serum, plasma, urine and 
cerebrospinal fluid. However, biological function of suPAR is not clear [50,388]. Elevated 
suPAR levels in S. pneumoniae bacteraemia on admission were prognostic for in-hospital 
mortality [389]. Elevated suPAR levels during the first 1-4 days in S. pneumonia, β-
haemolytic streptococci and Escherichia coli bacteraemia predicted increased 30-day in-
hospital mortality [390]. In addition, low levels of suPAR may be a positive predictor for 
overall survival in patients with sepsis of mixed aetiology [391].  
Two meta-analyses have evaluated the potential use of suPAR in critically ill intensive care 
patients, as a prognostic marker for in-hospital mortality and as a diagnostic marker for 
infection [53,54]. In the study of Backes et al., suPAR had a low diagnostic value in 
differential diagnosis of infection in patients with SIRS [53]. On the other hand, the 
prognostic value of suPAR was significant and complementary to other biomarkers and 
clinical classifications in the study of Donadello et al. [54]. In conclusion, these studies 
emphasised that elevated suPAR predicts mortality in sepsis, but is not diagnostic for 
infection in SIRS patients. 
2.8.2. Soluble apoptosis biomarkers  
Apoptosis, or active gene-directed cell death, is both a physiological and pathologic 
phenomenon [392]. When it is triggered by death-receptor pathway markers, measurable 
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concentrations of soluble Fas protein (human membrane protein, member of necrosis 
factor proteins) and Fas protein ligand (both studied as apoptosis biomarkers) are 
produced. Increased levels of soluble Fas protein were detected in patients with sepsis and 
multiple organ dysfunction syndrome [393]. Soluble Fas protein may be a therapeutic 
target in preventing post traumatic hyperinflammation [394]. In patients with bacteraemia, 
including 24% patients with SAB, apoptosis biomarkers were found not to be prognostic, 
but they correlated with high SOFA score in patients with bacteraemia [395]. 
2.8.3. Pentraxin 3 
Pentraxin 3 (PTX3) is an acute phase protein. The of PTX3 as a diagnostic marker for 
infection and as a prognostic marker for mortality in critically ill patients was recently 
reviewed by Liu et al. [396]. Based on the evaluation of seven studies on critically ill patients 
with SIRS, PTX3 levels in patients with bacteraemia were found significantly higher than 
those in blood-culture negative patients. However, PTX3 levels were not significantly 
different in patients with gram-negative bacteraemia compared to those with gram-
positive bacteraemia. As a prognostic marker for mortality, PTX3 levels measured on days 
1-4 were significantly higher in patients with fatal outcome (both in 28-30 days and in 90 
days) compared to survivors. PTX3 is complementary, not superior, to the other commonly 
used biological markers CRP and PCT [396]. In one study including SAB patients, PTX3 was 
found to be an independent prognostic marker in sepsis and showed better prognostic 
value than CRP [397]. Another recent study evaluated PTX3 values upon admission and it 
revealed good prognostic value of fatal outcome in patients with confirmed bacteraemia. 
However, the proportion of SAB in patients in this study was not mentioned [398]. 
2.8.4. Procalcitonin  
PCT, a glycoprotein and a precursor of calcitonin, [399] is a useful marker in distinguishing 
serious infection from non-infectious diseases [400,401]. Originally, very high 
concentrations of PCT were measured in paediatric patients who had severe bacterial 
infections. Low levels were seen in patients who had viral infections, local bacterial 
colonization or infections without sepsis. In this same study, PCT levels were higher in 
severely burned children with infectious complications than those without an infection 
[400]. Later studies on adult SIRS patients also demonstrated that PCT levels have a 
significant predictive value for sepsis [402] and bacteraemia [403]. PCT appears to be 
valuable in discriminating blood contamination and clinical infection when coagulase-
negative staphylococci were cultured from blood [404]. In addition, there seems to be 
some predilection of PCT for gram negative bacteraemia, since higher PCT levels were 
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detected in bacteraemia due to gram-negative bacteria than gram-positive bacteraemia 
[405].  
In guiding antibiotic treatment, PCT may be effective. However, as reviewed recently, cost-
effectiveness, variable kinetics, and concerns related to the diagnostics of different 
infection foci and pathogens were found to limit the utility of PCT [406]. In a general 
emergency department (ED) patient population, evidence-based support for PCT in guiding 
antibiotic therapy was inadequate [407]. However, another study found that PCT had 
prognostic value of moderate accuracy in ED patients in identifying septic patients with 
fatal outcome [408]. A recent ICU study found that a combination of CRP, PCT and sepsis 
related SOFA-score together was better than those used separately in diagnosing sepsis as 
early as possible [409]. Finally, a meta-analysis of 21 studies on pneumonia and use of PCT 
concluded that elevated PCT was a risk factor for death in both health care-associated and 
community-associated pneumonia [410].  
2.8.5. Cell-free DNA 
The presence of cell-free DNA (cf-DNA) in human blood was first detected in 1984 [411]. 
Circulating cf-DNA levels are related to necrosis, apoptosis and cell lysis [412,413].  
cf-DNA levels are elevated in septic patients [414]. In patients with septic shock, cf-DNA 
levels are significantly compared to patients with severe sepsis [415]. The diagnostic 
accuracy of cf-DNA is equal with PCT but better than CRP in identifying infection in febrile 
patients. Normal cf-DNA levels excluded infection with 97% specificity in febrile patients, 
and high concentrations of cf-DNA are prognostic of fatal outcome [416]. In one study on 
bacteraemic patients, which also included SAB patients, cf-DNA was demonstrated to be 
an independent prognostic marker for increased mortality [417]. In another study in sepsis 
patients, cf-DNA demonstrated independent prognostic value of mortality in patients with 
severe sepsis [418].  
2.9. Specific biomarkers in Staphylococcus aureus infections 
2.9.1. Teichoic acid and antistaphylolysin  
The teichoic acid antibody (TAA) assay and antistaphylolysin (ASTA) are among the oldest 
serological tests in detecting S. aureus infection. Both have been frequently used in clinical 
practice to distinguish complicated from uncomplicated SAB [419,420]. TAA titre elevations 
1:2-1:4 were suggestive of S. aureus infection; a titer of 1:8 was particularly suggestive of 
S. aureus endocarditis [420,421]. TAA response to infection can be expected in the first 1-
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2 weeks [420], which makes it more useful in diagnosing the cause of a chronic rather than 
an acute infection [422]. Deep infection raised TAA levels in 80%-91% of patients with a 
verified deep infection. However, TAA response was also detected in 68% of patients with 
uncomplicated disease and even in 44% of healthy persons [423-425].   
ASTA was the first available diagnostic test for routine use, but is considered unreliable in 
diagnosing deep infection due to its low sensitivity [426]. Positive ASTA titers ≥2.0 IU/ml 
were detected in 32-62% of patients with a deep infection, including IE [427]. In 
dermatological patients, ASTA has been used because as it correlates better with the skin 
barrier function rather than with the actual stage of infection [428]. Although, TAA and 
ASTA have been widely studied and widely used in diagnosing S. aureus infection, no 
serological test is positive in all SAB patients or able to differentiate complicated from 
uncomplicated bacteraemia [429]. Due to poor serological response, TAA and ASTA were 
found not helpful in predicting presence of deep infections in SAB [29]. 
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3. AIMS OF THE STUDY 
The main aims were to elucidate the plasminogen activation by Staphylococcus aureus and 
to study prognostic markers in Staphylococcus aureus bacteraemia. 
The specific aims were to identify 
I the effect of Staphylococcus aureus and its surface proteins on plasminogen 
activation by staphylokinase and to characterise potential Staphylococcus 
aureus plasminogen receptors in vitro 
 
II the predictive value of C-reactive protein in identifying fatal outcome and 
deep infections in Staphylococcus aureus bacteraemia  
 
III the effect of CRP-gene polymorphisms on CRP levels in Staphylococcus aureus 
bacteraemia  
 
IV the prognostic value of suPAR in Staphylococcus aureus bacteraemia  
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4. MATERIALS AND METHODS 
4.1. Study population and bacteria  
Study I comprised of five S. aureus isolates from bacteraemic patients, five from patients 
with a superficial infection and one laboratory strain (Newman). The clinical isolates were 
obtained from the Laboratory of Bacteriology, Division of Clinical Microbiology, HUCH 
Laboratory Diagnostics, Helsinki University Central Hospital, Helsinki, Finland. 
Studies II-IV were based on a previous prospective randomised multicenter study of 430 
patients where standard treatment with or without a fluoroquinolone (trovafloxacin or 
levofloxacin) were compared. Patients with a positive blood culture for S. aureus, were 
collected consecutively in five university and seven central hospitals from 1999 to 2002. 
The exclusion criteria were: age under 18 years, imprisonment, pregnancy, breastfeeding, 
epilepsy, bacteraemia in the previous 28 days, polymicrobial bacteraemia (≥3 microbes), 
allergy to any quinolone antibiotic, previous tendinitis during a fluoroquinolone therapy, 
prior fluoroquinolone use for more than 5 days before randomization, positive culture for 
S. aureus only from a central intravenous catheter, meningitis, neutropaenia (<0.5×109 
cells/L) or failure to provide informed consent. Patients with MRSA bacteraemia and strains 
resistant to any fluoroquinolone were excluded.  
In Study III the patient population was part of the whole 430 patient population from the 
Study II and included patients from one center, Helsinki University Hospital, as the 
permission for genetic testing was asked only from these patients. Blood samples for 
genetic testing samples were obtained from 151 of 158 patients from the study site. Blood 
samples from three patients could not be obtained for further analysis and three patients 
were rejected due insufficient DNA yield. In total, 145 patients were included in this study 
from Helsinki University Central Hospital. 
Study IV included a total of 59 patients from Helsinki University Central Hospital (from the 
whole 430- patient population). The patients were selected in consecutive numerical order 
such that they belonged to one of three groups: 1) death in 28 days, 2) deep infection, 3) 
no deep infection. The patients were required to have serum samples from the first 10 days 
after positive blood culture for S. aureus (with the exception of patients with fatal 
outcome). The objective was to include at the least 15 patients in each group. 
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4.2. Study designs 
Study I was a basic research study designed to clarify the possible role of S. aureus cells to 
SAK plg activation and characterize plasminogen binding structures of S. aureus. 
Studies II-IV were based on data collected in a prospective study where blood samples for 
CRP and WBC count were measured on the day of positive blood culture and every other 
day thereafter throughout the first week and subsequently twice a week during the 
hospital stay and at 28 days. Clinical characteristics, underlying diseases and predisposing 
factors were stratified per 30-day mortality and presence of deep infection.  
Six common SNPs of the CRP gene were genotyped in blood samples to assess the possible 
impact of genetic polymorphisms on complicated disease course and CRP response (III). 
First week CRP levels and distribution and characteristics of underlying diseases were 
stratified per genotype distribution.  
Study IV used the prospectively collected serum samples for suPAR analyses on day three, 
four and ten, and one month after the first positive S. aureus blood culture. The mean 
interval from the blood culture to the first suPAR sampling was three days (standard 
deviation 1.1; range 2–5 days). Characteristics and underlying diseases were stratified 
according to fatal outcome at one month and presence of deep infection. Median suPAR 
levels on days 3, 4, 10 and 30 were compared between these groups to determine whether 
elevated suPAR levels could predict fatal outcome or presence of deep infection in SAB. 
4.3. Laboratory methods 
4.3.1. Methods in Study I 
4.3.1.1. Bacterial cultivation and SAK phenotypic status 
Bacteria were grown in Todd- Hewitt broth overnight and pelleted by centrifugation. The 
bacterial pellets were washed twice with phosphate-buffered saline (PBS) and suspended 
in the same buffer containing bovine serum albumin (BSA). SAK producer status of S. aureus 
was determined by measuring the SAK activity in the spent overnight culture medium. In 
brief, plg, spent culture medium from overnight cultures and chromogenic substrate S-
2251 (Chromogenix) were incubated. The cleavage of the S-2251 was measured 
spectrophotometrically (Ultrospec II, LKB/Wallac). 
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4.3.1.2. Iodogen method and plg binding 
For plg binding experiments, plg was labelled with carrier-free Na 125I by the Iodogen 
method. In brief, the Iodogen oxidant (Sigma) solution was coated on the walls of the glass 
reaction tube. Radioiodination was then initiated by the addition of plg and Na 125I and 
terminated by removal of the reaction mixture. Plg binding was determined by incubating 
bacteria with radioactive labelled plg. The bacterial cells were pelleted and washed twice 
and radioactivity associated with bacteria was quantified with an γ-counter 1270 
Rackgamma II (LKB/Wallac). 
4.3.1.2. Lysostaphin treatment and isolation of plg binding proteins 
Isolation of S. aureus surface proteins started with lysostaphin treatment. In brief, in 
lysostaphin treatment bacterial suspension was incubated with recombinant lysostaphin 
(Applied Microbiology, Inc., New York, N.Y.), ribonuclease and deoxyribonuclease (Sigma) 
in the presence phenylmethylsulfonyl fluoride (Sigma) and ethylmaleimide (Sigma). Intact 
bacterial cells were removed by centrifugation, and the supernatants were incubated at 
80°C to stop the enzyme activity. Proteins interacting with plg were isolated by passing 
lysostaphin digest through a plg-Sepharose column. After that, the column was washed 
with PBS. The bound proteins were eluted by epsilon-aminocaproic acid (Fluka Chemie AG). 
Possible trace amounts of plasmin were inactivated with aprotinin (Sigma).  
4.3.1.3. Measuring activation of bacteria-bound and soluble plg by SAK  
Activation of plg was detected by incubating plg, SAK, α2AP, and chromogenic substrate S-
2251 in the presence of different concentrations of intact bacteria. In addition, solubilized 
S. aureus cell wall proteins, were used instead of intact bacteria. The cleavage of S-2251 
was measured spectrophotometrically. The quantity of plg bound to bacteria was 
determined by incubating radioactive labelled plg solution with S. aureus cells. 
Subsequently, cells were washed and the radioactivity associated with bacteria was 
counted. Plasmin activation was performed by incubating equal amounts of bacteria-
bound or soluble plg, as judged by the radioactivity, with SAK in the presence of S-2251. 
The cleavage of s-2251 was measured spectrophotometrically. 
4.3.1.4. Bacterial surface proteins ligand blotting 
Lysostaphin digest or eluted proteins from Sepharose (Pharmacia)-plg affinity column were 
run on sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) [430] in 
order to separate the plg-binding proteins. Proteins were then transferred 
electrophoretically to nitrocellulose membrane (Amersham, Hybond-C extra) and stained 
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to visualize the transferred proteins. The membrane was then destained and saturated 
with defatted milk powder in buffer solution and treated with plg. After several washes, 
the membrane was treated with rabbit anti-human plg dilution. The membrane was 
washed again and incubated in solution of affinity-purified antibodies to rabbit 
(immunoglobulin G) IgG (Jackson Immunoresearch Laboratories, Westgrove, PA, USA). 
Nitrocellulose membrane bound plg was revealed by 1,3,4,6-tetrachloro-3α,6α -
diphenylglycouracil treatment of the membrane. 
The cell wall proteins isolated by the affinity chromatography were separated by 
electrophoresis using SDS-PAGE gels. The protein bands were excised from the gel, washed, 
reduced, and digested with sequencing-grade trypsin. The resulting peptides were 
solubilized and filtered. The peptides were separated in a reversed phase high performance 
liquid chromatography system. After elution and detection of the peptides, individual 
peptides were sequenced by an automatic amino acid sequencer, Procise 494A (Perkin 
Elmer, Applied Biosystems Division, Foster City, USA). Peptide separation and sequencing 
were done in Protein Chemistry Unit and Institute of Biomedicine, Biomedicum, Helsinki, 
Finland and Laboratory of Protein Chemistry, Institute of Biotechnology, University of 
Helsinki, Helsinki, Finland, respectively. 
4.3.2. Methods in Studies II-IV 
4.3.2.1 CRP concentrations and white blood cell counts (Studies II-IV) 
 Serum CRP concentrations and WBC counts were measured in study sites by standard 
laboratory methods.  The serum or plasma (plasma instead of serum was used after 
18.3.2002) was analysed by automatic immunoturbidimetric method using analysers 917 
or Modular PP-analyser (Hitachi Ltd, Tokyo, Japan) and Tina-quant CRP reagents (Roche 
Diagnostics, Tina-quant CRP). For both methods, the normal value of CRP concentration 
was <10mg/L. In Study III leukocytosis was determined if WBC count was over 12×109 
cells/L. 
4.3.2.2. DNA extraction, sequencing and genotyping (Study III) 
Deoxyribonucleic acid (DNA) extraction, sequencing and genotyping were done in co-
operation with the National Institute of Health and Welfare, the Unit of Public Health 
Genomics, Helsinki, Finland. DNA was extracted by the phenol chloroform method. DNA 
was quantified by measuring absorbance at 260 nm and by Pico Green fluorescence assay 
(PicoGreen dsDNA Quantitation Kit, Molecular Probes, Carlsbad, USA). SNPs were detected 
by analysing primer extension products from amplified genomic DNA. For detection of 
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SNPs, Sequenom MassArray system with the homogeneous Mass Extension reaction 
(Sequenom, San Diego, USA) was used. MassArray design software was used to design PCR 
and extension reactions. For these PCR and extension reactions, 10 ng of template DNA 
was used. In all samples, six common SNPs of the CRP gene (rs27954521, rs3091244, 
rs1800947, rs1130864, rs1205 and rs3093075) were genotyped. The six SNPs selected were 
haplotype bin tagging SNPs. They covered the whole gene and large parts of the 
untranslated regions of the 5ʹ and 3ʹ ends of the gene. 
4.3.2.3. suPAR analytics (Study IV) 
suPAR levels were measured in the Clinical Research Centre, Copenhagen University 
Hospital, Hvidovre, Denmark. The suPARnostic™ kit (ViroGates, Copenhagen, Denmark) 
was used to measure the suPAR levels. The kit consists of catching monoclonal antibody 
pre-coated plates and a horseradish peroxidase labelled detection monoclonal antibody. 
Sample and detection antibody in dilution buffer in duplicates were added to the pre-
coated plate and incubated for 1 h. Following washing substrate was added for 20 min and 
the reaction was stopped with sulphuric acid. The plates were measured at 450 nM with a 
reference distance of 630 nM. 
4.4. Statistics 
The statistical program used in Studies II-IV was SPSS® (SPSS Inc., Chicago, IL, USA); version 
14.0 in Study III, 17.0 in Study IV, and 20.0 in Study II.  
In Studies II-IV, normality of continuous variables was tested by Kolmogorov-Smirnov and 
Shapiro-Wilks tests. Differences between skewed variables were assessed by the Kruskal-
Wallis H test and parametric tests were chosen when possible. 
Chi-square test or Fisher’s exact test was used when appropriate to analyse the 
associations between categorical variables. For skewed variables, heterogeneity of groups 
was assessed with the Kruskal-Wallis H test. Odds ratios with 95% confidence intervals (CI) 
were determined to estimate the significance of differences between the groups. All tests 
were two-tailed and the level of significance was considered p<0.05. Interquartile range 
(IQR), was defined as the difference between the third and the first quartile. Receiver 
operating characteristics (ROC) curves analyses were performed to find cut-off values of 
CRP and WBC in predicting fatal outcome and presence of deep infection focus (II).  Cox 
regression analysis, adjusted with predictors of fatal outcome, was calculated to determine 
hazard ratios for CRP and WBC count cut-off values predicting mortality. Odds ratios (OR) 
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for factors associated with the presence of deep infection were analysed by binary logistics 
regression analysis. 
In Study II, ROC curve analysis for 30-day mortality and the presence of deep infection was 
calculated to determine cut-off values for CRP and WBC count. The area under the curve 
(AUC) was calculated for each ROC. The cut-off points for general optimal tests were chosen 
to optimise the rate of true positives whilst minimising the rate of false positives. Cox 
regression analysis adjusted with characteristics, predisposing factors and severity of 
illness, was performed to determine hazard ratios of CRP and WBC cut-off values for 30-
day mortality. Adjusted ORs for factors associated with the presence of deep infection 
focus were analysed by binary logistic regression. Both multivariable analyses included 
significant covariates (p<0.2) by the forward selection method using the Akaike information 
criteria (AIC) [431].  
In Study III, genotypic frequencies within SNP loci were compared to values expected from 
the Hardy-Weinberg proportion. Associations between explanatory variables and outcome 
were calculated by linear regression univariate analysis. Multivariate regression analysis in 
studies III and IV were performed such that clinically meaningful and significant (P<0.05) 
variables associated in univariate analysis were all included in the model and were included 
in order of strength of their association with the outcome. Contribution to variance and 
possible collinearity with variables in the model was assessed when a new variable was 
added. False discovery rate analysis (FDR) [432] was applied for the multiple comparisons 
in Study III. 
4.4. Definitions 
Infection foci were definite if verified by radiological, bacteriological or pathological 
investigations but regarded as suspected if based on clinical findings only. However, both 
definite and suspected infection foci were pooled together in analyses. Deep infection 
included: pneumonia, endocarditis, deep-seated abscess, septic arthritis, osteomyelitis, 
septic thrombophlebitis, mediastinitis, UTI, CVC infection, foreign body infection, verified 
bacteraemia and CNS infection. In addition, a deep-seated abscess was defined as 
parenchymal, lung, peritoneal, subphrenic, gynaecological and pericardial abscess or 
pleural empyema. IE was defined using the modified Duke criteria as definite or possible 
by echocardiographic, clinical and pathological data [433]. CVC infection was defined 
according to the guidelines of the Infectious Diseases Society of America [434]. Severity of 
underlying diseases and prognosis were described as healthy, nonfatal, ultimately fatal or 
rapidly fatal using the criteria of McCabe and Jackson [216]. Bacteraemia was defined as 
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CA when the positive blood culture was received within 48 hours of hospital intake and 
there was no preceding hospitalization in seven days. SAB was health-care associated when 
positive blood culture was received ≥48 hours after hospital admission or the patient had 
been in haemodialysis within the past two months or had lived in a long-term care facility.  
[433]. Sepsis was defined as severe sepsis when hypotension, hypoperfusion or organ 
failure were detected as described [435]. The time to defervescence was measured in days 
until the axillary temperature was ≤37.5°C. Altered mental status was defined as 
unconsciousness or severe confusion. IDUs were patients who had injected drugs 
intravenously 6-month prior randomization. 
4.5. Ethical statement 
Study I comprised experiments only with bacterial strains originating from patients with 
bacteraemia or with superficial infections; patient data was not included. The protocol for 
Studies II-IV was approved by the ethics committees of all study sites, including the Ethics 
Committee of Helsinki University Hospital and the Finnish National Agency for Medicines. 
Written informed consent was obtained from all patients or their representatives. 
However, severely ill patients were also included without signed consent, because they 
were presumed to benefit from the study medication. A signed informed consent was 
taken in all cases afterwards by the patient or by a representative. 
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5. RESULTS 
5.1. Staphylococcus aureus and activation of plasminogen by 
staphylokinase (Study I) 
5.1.1. Bacteria and plasminogen activation 
It was first shown that plasmin activity was effectively inhibited by α2AP in a reaction 
solution containing only plg, SAK and α2AP. When bacteria cells were added to the reaction 
solution, this led to a dose-dependent increase in plasmin activity, which was revealed by 
the cleavage of chromogenic substrate s-2251 (Study I; Fig.1.A). This enhancing effect of 
intact S. aureus bacterial cells was demonstrated with all strains, including both SAK 
producers and non-producers. There is a correlation between the capacity of bacteria to 
bind plg and the enhancing effect on plg activation (Study I; inset of Fig.1.A). It was also 
shown that only plg bound to bacterial cells, not free plg, was activated by SAK and 
exogenous SAK was necessary for the activation to occur (Study I; Fig.1.B). 
5.1.2. Cell wall proteins and plasminogen activation  
At a concentration of 50-200 μg/ml, cell-wall solubilised plg-binding components enhanced 
plg activation and eliminated α2AP-dependent inhibition of active plasmin (Study I; hatched 
bars in Fig. 2.). The enhancing effect and ability to resist α2AP dependent inhibition of the 
cell-wall containing solution were shown to stop after passage through a plg affinity column 
(Study I; dark grey bars in Fig. 2). Proteins eluted from the column were able to protect and 
enhance again plg activation to plasmin in the presence of α2AP. When the ability of eluted 
proteins and whole lysostaphin were compared, 25 μg/ml plg-binding proteins were as 
effective as 100-200 μg/ml of whole lysostaphin digest in generating plasmin activation. 
5.1.3. Staphylococcus aureus plasminogen binding proteins  
Plg-binding proteins eluted from a Sepharose-plg affinity chromatography column were 
analysed by SDS-PAGE. Major 59-, 56-, and 39-kDa, and minor 45- and 43-kDa bands were 
detected. Plg binding to bands was further studied and visualised bands are shown (Study 
I; Fig. 3.). The affinity of plg for the 59- , 56- and 43-kDa proteins was strong, while the 
affinity for the 39- and 45-kDa proteins was barely detectable. Peptide sequences were 
then compared to protein databases. Homologies between the 59-, 56-, and 43-kDa 
proteins and known S. aureus proteins were revealed. The 59-kDa protein corresponded to 
5’-monophosphate dehydrogenase (IMPDH), the 56-kDa protein with α-enolase and 43-
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kDa protein with ribonucleotide reductase β-chain. This enabled reliable identification of 
major plg-binding proteins. The 45-kDa protein band was too faint for identification and 
the 39-kDa protein did not match any known protein. 
5.2. Predictive value of CRP in identifying fatal outcome and deep infections 
in Staphylococcus aureus bacteraemia (Study II) 
5.2.1. 30-day mortality and prognostic factors 
In Study II, 53 out of a total 430 S. aureus bacteraemia patients had a fatal outcome within 
30 days. In univariate analysis, age >60 years (n=43/53, 81%, OR 5.0, p<0.0001), 
immunosuppressive treatment (n=16/53, 30%, OR 3.5, p<0.0001), chronic alcoholism 
(n=11/53, 21%, OR 2.4, p<0.032), chronic renal failure (n=14/53, 26%, OR2.6, p=0.010), 
malignancy (n=13/53, 25%, OR 2.1, p=0.038), ultimately or rapidly fatal underlying disease 
(n=31/53, 59%, OR 4.6, p<0.0001), severe sepsis during the first three days (n=12/53, 23%, 
OR 4.1, p=0.001), any deep infection focus (n=51/53, 96%, OR 6.5, p=0.002), pneumonia 
(n=34/53, 64%, OR 3.9, p<0.0001) and endocarditis (n=17/53, 32%, OR 2.6, p=0.006) were 
all significantly associated with 30-day mortality. Health care-associated infection, 
presence of a foreign body, diabetes, liver disease, deep-seated abscess, osteomyelitis, 
foreign body infection and septic arthritis were not significantly associated. Mortality 
among IDUs was lower (n=1/53, 1.9%, OR 0.15, p=0.029) than non-users. 
In multivariate analysis, prognostic factors for 30-day mortality in SAB were: age >60 years 
(HR 4.2, p <0.0001), chronic alcoholism (HR 2.7, p=0.017), chronic renal failure (HR 2.3, 
p=0.037), ultimately or rapidly fatal underlying disease (HR 2.1, p=0.033), pneumonia 
(HR2.0, p<0.033) and endocarditis (HR 2.5, p=0.004). 
5.2.2. Deep infection and associated factors 
In 352 (82%) patients, a deep infection focus was found during the 30-day surveillance 
period. However, in three days starting after the positive blood culture result, a majority of 
all deep foci were evident and found in 325 (75%) patients. Deep infection foci in order of 
prevalence were: deep-seated abscess in 185 (43%), osteomyelitis in 141 (33%), 
pneumonia in 152 (35%), infection of foreign body in 79 (18%), IE in 74 (17%), and septic 
arthritis in 56 (13%) patients. In univariate analysis, a significantly associated risk factor for 
the presence of deep infection focus was IDU (OR 11, p=0.002); male gender, chronic renal 
failure and malignancy were not associated. Health care-associated origin of SAB (OR 0.48, 
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p=0.006) and presence of foreign body (OR 0.50, p=0.010) lowered the risk for deep 
infection focus.  
5.2.3. CRP levels and outcome  
The mean CRP level was reached its maximum at the time the positive blood culture was 
collected (Study II; Fig 1.A). Starting from the day four after positive blood culture, the 
mean CRP level in patients with fatal outcome differed from those in survivors. The 
difference remained significant during the one-month observation period. CRP levels 
stratified according to one-month mortality are shown (Study II; Fig 1.B). At the earliest, 
CRP levels on day four predicted mortality; the median in deceased patients was 127 mg/L 
(IQR, 97 mg/L) and 91 mg/L (IQR 96 mg/L, p=0.005) in survivors. CRP concentrations and 
WBC counts at the time of positive blood culture did not predict 30-day mortality as 
analysed by ROC curve analyses. Day four CRP >103 mg/L was a significant predictor of fatal 
outcome, but WBC count >8.0 x109/L was not (Table 3). On day seven, CRP >66mg/L and 
WBC count >9.8 x109/L and on day 14 CRP >61 mg/L and WBC count >8.6 x109/L were 
significant in predicting mortality (Table 3). ROC curve analyses predicting 30-day mortality 
using CRP levels and WBC counts on day four and seven (Figure 1) and on day 14 (Figure 2) 
are shown. 
 
Table 3. Cut-off values for predicting 30-day mortality for CRP and WBC count on days 
four, seven and 14 in Staphylococcus aureus bacteraemia according to ROC analysis. 
AUC= area under the curve in ROC analysis. The p-value for odds ratio (OR) is shown. 
CRP  Four days Seven days 14 days 
AUC (95% 0.65 (0.55- 0.68 (0.58- 0.86 (0.79-0-94) 
cut-off  103 mg/L 66 mg/L 61 mg/L 
    sensitivity 77% 73% 82% 
    specificity 55% 55% 80% 
OR (95%, CI) 2.6 (1.4-4.8) 2.6 (1.3-5.1) 19.8 (6.6-59.4) 
   p-value 0.004 0.005 <0.0001 
WBC count    
AUC 0.60 (0.49- 0.70 (0.62- 0.80 (0.70-0.92) 
cut-off 8.0 x109/L 9.8 x109/L 8.6 x109/L 
   sensitivity 86% 77% 77% 
   specificity 41% 62% 78% 
OR (95%, CI) - - 6.5 (2.8-15.0) 
  p-value - - <0.0001 
52 
 
  
 
Figure 1. ROC curve analysis of CRP levels (continuous line) and WBC count (dotted line) 
for day four (left panel) and for day seven predicting 30-day mortality in 430 
Staphylococcus aureus bacteraemia patients (right panel). 
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Figure 2. ROC curve analysis of CRP levels (continuous line) and WBC count (dotted line) 
for day 14 predicting 30-day mortality in 430 Staphylococcus aureus bacteraemia 
patients. 
The prognostic value of WBC count improved when both low (<4.5 x109/L) and high (above 
reference limit) WBC counts were combined as abnormal WBC count. In univariate 
analyses, odds ratios (OR, 95% CI) were as follows: fall of CRP <50% in 14 days (OR 5.7, 95% 
2.5-13.1; p=0.0001) and fall of CRP <50 % between days 7-14 (OR 8.5, 95% CI 2.5-29.2; p 
<0.0001), day four WBC count <4.5 or >10.3 x109/L (OR 2.0, 95% CI 1.1-3.7; p=0.024) and 
day seven WBC count <4.5 or >9.8 x109/L (OR 5.8, 95% CI 2.6-12.8; p <0.0001).  
Table 4 shows significant prognostic factors for 30-day mortality due to SAB as analysed by 
multivariate analysis (comprising characteristics, predisposing factors and severity of illness 
in patients Study II; Table 1). Table 5 shows significant prognostic factors for 30-day 
mortality as analysed by multivariate analysis (comprising factors listed in the Study II; 
Table 1) and cut-off values for CRP levels and WBC counts (listed in Study II; Table 2). The 
predictive power of multivariate analysis with cut-off values for CRP levels, WBC counts 
and decline of CRP <50% appeared superior (Table 5) compared to the analysis without 
(Table 4). 
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Table 4. Significant prognostic characteristics, predisposing factors and severity of illness, 
calculated by multivariate analysis, for 30-day mortality in 430 SAB patients. Cut-off 
values for CRP levels and WBC counts were excluded.  
Significant prognostic factor Hazard ratio and 95% CI Multivariate analysis p-
value 
Age >60 years 4.2 (2.0-8.6) <0.0001 
Chronic alcoholism 2.7 (1.2-6.1) 0.017 
Chronic renal failure 2.3 (1.1-5.1) 0.037 
Ultimately or rapidly fatal 
disease 
2.1 (1.1-4.0) 0.033 
Pneumonia 2.0 (1.1-3.7) 0.033 
Endocarditis 2.6 (1.4-4.9) 0.004 
 Model overall predictive power:  -2 log likelihood 547.718, chi-square 100.102, P <0.0001.  
 
Table 5. Significant prognostic characteristics, predisposing factors and severity of illness, 
calculated by multivariate analysis, for 30-day mortality in 430 SAB patients. Cut-off 
values for CRP levels and WBC counts were included. 
Significant prognostic 
factor 
Hazard ratio and 95% CI p-value 
CRP >103 mg/L on day 
four 
3.5 (1.2-10.3) 0.024 
CRP >61 mg/L on day 14 3.6 (1.1-10.3) 0.039 
WBC >8.6 x109/L on day 
14 
8.2 (2.9-23.1) <0.0001 
Age >60 years 3.6 (1.1-11.5) 0.029 
Ultimately or rapidly 
fatal disease 
6.5 (2.4-17.6) <0.0001 
Pneumonia 8.1 (2.5-25.8) <0.0001 
Model overall predictive power: -2 log likelihood 169.320, chi-square 92.437, p<0.0001. 
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5.2.4. Predictors of deep infection foci 
The mean CRP level in patients with and without a deep infection focus are shown Figure 
3. CRP levels were significantly higher already on the day of positive blood culture in 
patients with deep infection compared to patients without and also during the 30-day 
surveillance period. 
 
Figure 3. Mean CRP concentrations in 351 Staphylococcus aureus bacteraemia patients 
with a deep infection focus (divot bars) and in 79 Staphylococcus aureus bacteraemia 
patients with no deep infection focus (large grid bars).  
ROC curve analysis for CRP levels and WBC count gave cut-off values for predicting the 
presence of a deep infection focus. CRP cut-off values on the day one, seven and 14 were 
significant in predicting a deep infection focus whereas WBC count was significant only on 
day 7 (Figure 4) and (Table 6). 
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 Figure 4. ROC curve analysis of CRP levels and WBC count for predicting presence of any 
deep infection focus in 430 Staphylococcus aureus bacteraemia patients during 30-day 
surveillance period.  
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 Table 6. Cut-off values for predicting deep infection for CRP and WBC count on days one, 
four, seven and 14 in Staphylococcus aureus bacteraemia according to ROC curve analysis. 
AUC=area under the curve in ROC curve analysis. The p-value for odds ratio (OR) is 
shown. 
CRP Day 1 Day 4 Day 7 Day 14 
AUC (95% CI) 0.74 (0.67-0.81) - 0.75 (0.68-0.81) 0.70 (0.64-0.77) 
cut-off  108 mg/L - 44 mg/L 22 mg/L 
sensitivity 77% - 68% 59% 
specificity 60% - 67% 68% 
OR (95% CI) 4.9 (2.9-8.2) 3.4 (2.0-5.6) 5.7 (3.2-10) 4.4 (2.4-8.1) 
p-value <0.0001 <0.0001 <0.0001 <0.0001 
WBC     
AUC 0.55 (0.46-0.63) - 0.65 (0.58-0.72) 0.56 (0.49-0.63) 
P 0.236 - p <0.0001 0.153 
cut-off not determined 8.0 x109/L 8.5 x109/L 7.25 x109/L 
sensitivity - - 59% 44% 
specificity - - 62% 75% 
OR (95%, CI)  2.2 (1.4-3.7) 2.4 (1.4-4.0) 2.1 (1.2-3.8) 
p-value  0.002 0.001 0.010 
 
In multivariate analysis of deep infection focus, prognostic factors included: IDU, male 
gender, chronic renal failure, malignancy, health care-associated SAB and foreign body. 
Prognostic factors and cut-off values for CRP levels, WBC counts and falls of CRP <50% 
predicting presence of deep infection focus (listed in original article) were included in 
multivariate analysis (Study II; Table 3). Significant prognostic factors from multivariate 
analysis are listed in Table 7. 
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Table 7. Prognostic factors for deep infection focus in 430 SAB patients. The p-value for 
multivariate analysis is shown. IDU= intravenous drug use. 
Predictor of deep infection focus Odds ratio and 95% CI p-value 
IDU 11.9 (1.5-93.2) 0.018 
Day one CRP >108 mg/L  2.6 (1.3-4.9) 0.005 
Day 14 CRP >22 mg/L  3.9 (1.6-9.5) 0.003 
5.3. Genetic polymorphism of the CRP gene and a deep infection focus 
determine maximal serum CRP level in Staphylococcus aureus 
bacteraemia (study III) 
5.3.1. Characteristics and underlying diseases 
145 SAB patients with permission for genetic analyses from Helsinki University Hospital 
were included in Study III. The majority of patients (66%) were male and mean age was 
52±17 years. In 60% of patients,  infection was hospital-associated, 47% had a prosthetic 
or intravascular device, 25% had been in previous surgery, 21% had CVC, 19% had a history 
of intravenous drug abuse, 6% had used corticosteroids ≥1 month, 6% were alcohol 
abusers, 10% needed immunosuppressive therapies, 22% had coronary artery disease, 26% 
were diabetics, 26% had chronic lung disease, 18% had chronic renal failure, 3% had hepatic 
cirrhosis, 6% had autoimmune disease, 16% had malignancy, 4% were HIV positive and in 
68% McCabe´s classification was healthy or nonfatal. All diagnosed deep infection foci 
during the 3-month surveillance period are shown in Table 8. 
Table 8. All deep infection foci diagnosed in 3-month surveillance period 
Infection foci  N (%)  
Deep infection  122(84) 
Pneumonia 62 (43) 
Any deep abscess 71 (49) 
Osteomyelitis 60 (41) 
Any foreign body 29 (20) 
Endocarditis 28 (19) 
Septic arthritis 19 (13) 
Mediastinitis 10 (7) 
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5.3.2. CRP gene single nucleotide polymorphisms 
CRP gene SNPs genotypic distribution followed the Hardy-Weinberg equilibrium. Two of 
the of selected bin tagging SNPs rs3091244 and rs2794521 originated from the promoter 
region, rs1205 and rs3093075 from 3´ flanking region, rs1800947 from exon 2 and 
rs1130864 and from 3´ UTR region. All six SNPs were found to be in strong linkage 
disequilibrium (LD) by Haploview 3.2 Program. In full LD was A-minor allele of rs3091244 
with rs3093075 and T-minor allele of rs3091244 with rs1130864. Within one haplotype 
block were all other SNPs, except rs1205. 
5.3.3. CRP levels and single nucleotide polymorphisms 
Maximal CRP levels during the first week of SAB were found to be significantly higher in 
patients who carried the minor allele of rs3091244 or the T-minor allele rs3093075 
compared to patients who were not carriers of these minor alleles (Table 9). Strong LD 
between these two SNPs explained similar results. CRP levels at the time of the blood 
culture or at day seven were not affected by any SNPs analysed in additive and recessive 
models. CRP levels on the day of the positive blood culture, on day seven and maximal CRP 
levels during the first week were stratified by additive and recessive genotypes of 
rs3091244 (Study III; Table 2). 
Table 9. Maximal CRP levels during the first week in SAB patients stratified according to A-
minor allele distribution of SNP rs3091244. The p-value for Kruskal Wallis H test is shown. 
n=number of patients. IQR=Interquartile range. 
Maximal CRP mg/L during the first week (IQR) Genotype distribution of rs3091244 (n) 
182 (167) TT (21) Additive model   
 p=0.023 193 (157) TC (55) 
299 (202) TA (4) 
163 (102) CC (28) 
280 (188) CA (8) 
179 (148) TT+TC+CC (104) Recessive model 
p=0.004 282 (169) TA+CA (12) 
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In addition, when demographic characteristics, underlying diseases and predisposing 
factors were stratified by the A minor allele of rs3091244, no differences in distribution of 
these were detected between A-minor allele carriers and non-carriers (Study III; Table 3).  
5.3.4. Maximal CRP levels 
Demographic and clinical factors that could impact maximal CRP levels (age, gender, body 
mass index, surgical intervention, deep infection focus, intravenous drug use and carrier 
status of rs3091244 A-minor allele) were analysed in univariate and multivariate analysis. 
Significant factors affecting maximal CRP level in univariate analysis were the presence of 
any deep infection focus and SNP rs3091244 A-minor allele carriage. Associations of any 
other SNPs analysed in recessive and additive models were not detected with maximal CRP 
levels. The adjusted model indicated that the presence of deep infection and A-minor allele 
explained 21.7% of the maximal CRP variation in SAB during the first week (Study III; Table 
4). 
All CRP gene SNPs were analysed in additive and recessive models. No associations with 
time to defervescence, leukocytosis, amount of deep infection foci, CVC-associated 
infection or mortality were detected. 
5.4. Elevated soluble urokinase plasminogen activator receptor (suPAR) in 
predicting mortality in Staphylococcus aureus bacteraemia (study IV) 
5.4.1. suPAR levels in Staphylococcus aureus bacteraemia 
A total of 59 S. aureus bacteraemia patients were divided into three groups based on 30-
day survival and on verified presence of a deep infection focus. All patients who died had 
a deep infection focus. The patients with fatal outcome were older and had ultimately or 
rapidly fatal disease more often than survivors (Study IV; Table 1).  
When patients were stratified according to 30-day outcome, suPAR levels in fatalities were 
higher at days three, four and 10 after the first positive blood culture compared to suPAR 
levels in survivors. No difference was found when suPAR levels in patients with no deep 
infection focus were compared to levels in patients with a deep infection focus (Table 10). 
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Table 10. Median suPAR levels in fatalities as compared to survivors and in survivors with 
or without deep infection. Data is shown as median suPAR levels ng/mL (range), n= 
number of patients. The p-value for the Mann-Whitney U-test is shown. 
 Fatalities Survivors p-value No deep 
infection 
Deep 
infection 
p-
value 
Day 3 12.3  
(5.7-64.6) 
n= 19 
8.4  
(3.7-17.6) 
n=40 
0.002 9.2 
(3.7-17.6) 
n=15 
7.9  
(5.0-16.3) 
n=25 
0.319 
Day 4 11.5  
(4.7-20.6) 
n=18 
7.1  
(2.5-15.2) 
n=40 
0.001 7.3  
(3.4-14.9) 
n=15 
6.6  
(2.5-15.2) 
n=25 
0.406 
Day 
10 
11.8  
(6.1-17.8) 
n=16 
6.5  
(2.3-17.3) 
n=40 
<0.0001 7.5  
(2.3-14.9) 
n=14 
6.1  
(3.0-17.3) 
n=20 
0.959 
 
5.4.2. suPAR as a prognostic marker in Staphylococcus aureus bacteraemia  
In ROC curve analysis, the prognostic value of suPAR was evaluated against CRP as a 
prognostic factor for fatal outcome. On day three, the area under the curve (AUC) for suPAR 
was 0.754 (95% CI, 0.615-0.894; p=0.003) and the AUC for CRP was 0.596 (95% CI, 0.442-
0.75; p=0.253), (Figure 6). ROC curve analysis gave a cut-off value of 9.25 ng/mL for suPAR 
on day three with a sensitivity of 0.79, a specificity of 0.68 and a positive likelihood ratio of 
2.5. When patient characteristics and underlying diseases were analysed by suPAR cut-off 
9.25 ng/mL, suPAR was >9.25 mg/mL in 64% of patients >65 years, in 64% having ultimately 
or rapidly fatal disease, in 46% having renal failure and in 36% with a CVC.  
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Figure 6. ROC curve analysis of suPAR levels (continuous line) and CRP levels (dotted line) 
for day three predicting 30-day mortality in 66 Staphylococcus aureus bacteraemia 
patients (right panel). 
In univariate analysis, the factors predicting mortality in 30-days and odds ratios were 
calculated: age >65 years, OR 5.2 (95% CI, 1.6-17.4; p=0.011), suPAR >9.25 ng/mL, OR 7.8 
(95% CI, 2.2-28.2; p=0.002), ultimately or rapidly fatal underlying disease, OR 6.5 (95% CI, 
1.9-22.2; p=0.002), presence of cerebral symptoms on the first three days, OR 4.1 (95% CI, 
1.1-15.3; p=0.042). In multivariate analysis, suPAR >9.25 ng/mL was analysed only with one 
factor (presence of cerebral symptoms), while other significant factors were omitted from 
the model. This was due to the significant collinearity of suPAR with age >65 years and 
presence of ultimately or rapidly underlying disease. In binary logistic regression analysis, 
adjusted with the presence of cerebral symptoms during the first three days in the 
beginning of the SAB, suPAR >9.25 ng/mL was associated with increased risk (OR 8.0; 95% 
CI, 2.1-30.5; p=0.002) for fatal outcome in 30 days in SAB.    
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6. DISCUSSION 
6.1. Enhanced activation of bound plasminogen on Staphylococcus aureus 
by staphylokinase 
In our study, the SAK-plasmin complex activating plg to plasmin was demonstrated to 
enhance and protect against the inhibitory effect of α2AP when complex was bound either 
to S. aureus cells or to plg- binding cell wall components. Purified cell wall components 
were shown to bind plg and were identified as S. aureus IMPDH, α-enolase and rRNR; these 
proteins might be S. aureus plg receptors. 
Our finding is consistent with earlier experiments showing that S. aureus bound to plasmin 
is effectively protected against the inhibitory effect of α2AP [436]. Enhanced activation of 
the SAK-plasmin(ogen) complex has been shown to take place when the complex is bound 
to fibrinogen [437]. We now observed that enhanced activation of plg occurs on the 
bacterial cell surface in direct correlation with bacterial plg binding capacity. We could 
demonstrate that binding of plg to S. aureus rendered plg more sensitive to SAK-mediated 
activation and this reaction occurred only when bacterial cells were present. Binding-
induced conformational changes in the plg molecule have been suggested as the 
mechanism responsible for enhanced activation [436]. Consistent with this theory, many 
studies have shown a strong fibrin-specific activity of SAK [438-440] 
SAK exhibits weak affinity to plg, but strong affinity for plasmin, which in theory is formed 
spontaneously in small amounts from plg. On the other hand, the SAK-plasmin complex, 
rather than the SAK-plg complex, activates plg to plasmin [116,441,442]. In our experiment, 
however, the plasmin activity of plg was eliminated with aprotinin preincubation. This was 
necessary to reduce the possibility of SAK-plasmin complexes, which are responsible for 
the enhanced activation as opposed to bacterial cells or purified cell wall proteins 
interacting with plg. 
Solubilised cell wall proteins, like whole bacterial cells, were shown to abrogate the α2AP-
mediated inhibition of plasmin and enhanced activation of plg by SAK. After treatment with 
immobilised plg, however, both the ability to resist α2AP and to enhance activation could 
be stopped. This demonstrated that the plg-binding ability of S. aureus is at least partly 
mediated by cell-surface proteins. The 59-, 56-, and 43-kDa proteins with strong plg-binding 
capacity were identified as staphylococcal IMDPH, α-enolase and RNR, respectively.  
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IMPDH is a nicotinamide adenine dinucleotide dependent enzyme that controls de novo 
synthesis of guanine nucleotides. IMPDH is an important target enzyme for a number of 
immunosuppressive agents and has provided potential therapeutic targets for the 
treatment of viral and parasitic diseases [443-445]. In addition, IMPHD has been suggested 
to be a potential biomarker in organ transplantation [446]. RNR is a known mediator of 
deoxyribonucleotide biosynthesis, which is required for DNA synthesis in all living cells. RNR 
could be a target for anti-proliferative therapeutic compounds in malignancies and also in 
parasitic, viral and bacterial diseases [447]. Both IMPDH and RNR are intracellular enzymes 
and have not been described earlier to have extracellular function. However, the excretion 
of cytoplasmic proteins in general is a known phenomenon in bacteria and eukaryotes and 
it is not likely due to cell lysis [107]. 
The extracellular location of intracellular glycolytic enzyme α-enolase has been described 
earlier in S. pneumonia. Consistent with our study, α-enolase is also expressed as a plg-
binding molecule on the surface of many bacteria, including S. pneumoniae [448], 
Mycoplasma fermentans [103] and Bacillus anthracis [104].  In Vibrio parahaemolyticus, 
enolase has been shown to bind plasminogen [449]. Surface-displayed α-enolase also 
bound fibronectin in Lactobacillus [450]. In addition, enolase like protein was observed to 
bind plasminogen on the outer membrane of Pseudomonas aeruginosa [451]. In 
Lactobacillus plantarum, enolase was characterised as a collagen-binding molecule [452]. 
Another intracellular glycolytic enzyme, glyceraldehyde-3-phosphate (GAPDH), has been 
shown to function not only as a transferrin receptor on S. aureus surface but also as a plg-
binding molecule [453]. In addition, in streptococci groups A, B and C, in gram-negative 
bacteria and in spirochetes, GADPH is an important plg receptor [79]. Accordingly, the 
glycolytic enzymes GADPH and α-enolase might have dual functions as glycolytic 
intracellular enzymes and also as bacterial surface plg receptors, representing a 
phenomenon known as moonlighting [454]. 
Limitations of our study include the possibility that some bacterial cells during overnight 
cultivation or lysostaphin digest may break. This may lead to release of intracellular 
enzymes together with cell surface proteins as complex. These complexes could be falsely 
interpreted as cell surface proteins. If so, the proteins from the Sepharose-plg would also 
contain intracellular enzymes associated with the cell wall proteins. However, all eluted 
proteins analysed by both SDS-PAGE and ligand blotting were shown to interact with plg. 
In addition, protein patterns of lysostaphin digest were not detected to differ depending 
on the presence or absence of 20% sucrose during digest. Sucrose was used during 
lysostaphin digest to prevent bacterial cells break-down. 
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According to our hypothesis, Staphylococcal plg-binding structures along with SAK 
production could form a system that enables bacteria to produce cell-surface α2AP-
protected protease activity. This could theoretically facilitate bacterial invasion and act as 
a virulence factor in invasive SAB. In contrast, other studies on S. aureus and SAK have 
found out that plg activation by SAK might reduce the severity of systemic infection [120]. 
S. aureus SAK production seemed to be associated with uncomplicated local infections in 
humans rather than with invasive systemic infections. SAK production was also shown to 
enhance only local subcutaneous spreading in skin infections [70] and to lead to less biofilm 
formation [27]. Most S. aureus strains causing infections to humans can produce SAK [22], 
whereas SAK producing S. aureus strains from veterinary infections are rare [70]. For 
unknown reasons SAK production appears to be an adaptation mechanism for S. aureus. 
Peetermans et al. described how SAK production enhances local spreading rather than 
systemic invasion. In their experiments, they demonstrated that SAK-mediated plasmin 
activity outside of abscess rapidly diminishes. This could be due to low bacterial and fibrin 
concentrations outside of an abscess [70]. However, SAK production as virulence factor of 
S. aureus, even after these studies, remains partly resolved. 
6.2. Predictive value of CRP in identifying fatal outcome and deep infections 
in Staphylococcus aureus bacteraemia  
CRP level and WBC count are common biomarkers followed in patients with SAB, however, 
cut-off values for predicting mortality or disease complications from deep infection focus 
are unknown. A clear definition of these values could assist in allocating resources, both 
diagnostic and therapeutic, to the SAB patients who need them most.  
In our study, we observed that by the fourth day after the first positive blood culture, CRP 
and (by day 14) WBC count were higher in patients with fatal outcome than survivors. 
Furthermore, already from the day of the positive blood culture, CRP level and (from day 
four) WBC count were higher in patients with a deep infection focus than patients without.  
Abnormal WBC count (also including low WBC count) and CRP level both predicted 
mortality; CRP starting from day four and abnormal WBC count from day seven. After 
adjustment with prognostic and predisposing clinical factors, however, only CRP on day 
four and 14 remained prognostic. Abnormal WBC count was prognostic only on day 14. Day 
four CRP >103 mg/L as a predictor of 30-day fatal outcome was consistent with other 
studies, as CRP on day one in critically ill patients with suspicion of sepsis did not predict 
in-hospital mortality [40,455]. Consistent with our study, a study on critically ill South 
Korean patients found that high CRP levels on day one were not predictors of poor 
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outcome. Interestingly, in this same study a decline in CRP (>36%) compared between days 
1-2 and 5-7 was predictive for reduced mortality [456]. In our study, we did analyse fall of 
CRP <50% as a predictor of mortality. In our univariate analysis, a fall of CRP <50% in seven 
and in 14 days were significant predictors of fatal outcome, but were not significant in 
multivariate analysis. This was probably because the fall of CRP <50% was not independent 
of CRP levels as a marker of mortality and only the most significant predictors remained 
significant. In contrast to our results, in one large Japanese study CRP >150 mg/L measured 
on admission was an independent predictor of 30-day in-hospital mortality [457]. In these 
studies, however, the patient populations had microbiologically heterogenous infections 
or the causative microbes were undefined; our study population included only S. aureus 
bacteraemia patients. In these studies, the patients were also more seriously ill than in our 
study and were in need of ICU treatment. These differences could partly explain the 
different results; the prognostic cut-off value of CRP might be microbe and disease specific. 
Mortality in our study was only 12% as compared to 14-23% in other SAB studies 
[159,207,284,458]. Limitation of our study may be the use of clinical drug research study 
population [4]. We may have missed critically ill patients due to recruitment problems. 
These patients may have been rejected due to very rapid disease progression and fatal 
outcome. In addition, without antibiotic study inclusion criteria more patient would have 
been included. Possible reasons for rather low mortality could be that patients with MRSA 
were not included and patients were treated with effective antibiotics from the beginning. 
In our prospective patient material, all patients received infectious disease specialist 
consultation, which is one key factor in lower mortality and in finding deep infection foci 
[459]. Possible limitation of our study was also the use of multivariate analysis for 
predicting mortality. Mortality was low and relatively small number of fatalities may have 
limited the power of the multivariate analysis. CRP and WBC count are also only predictive 
biomarkers, not real clinical determinants of prognosis, such as age or severity of disease. 
In addition, CRP and WBC count are not independent of each other, which may have caused 
certain collinearity. However, forward selection in multivariate analysis using Akaike 
information criteria may have mitigated the risk of collinearity. While mortality in SAB has 
not improved dramatically during last 10 years, treatment strategies have changed, 
suggesting that CRP cut-off levels from our study could still be valid today. 
CRP on day one was not prognostic for fatal outcome and this is consistent with the finding 
that CRP gene SNP rs3091244 A-minor allele and a deep infection focus determine the 
maximal CRP level in SAB (Study III). Possible limitation of our study is that CRP gene SNPs 
were not analysed in all 430 SAB patients. In genetic analysis of 430 SAB patients we could 
have detected associations of CRP gene SNPs also with low CRP levels or other clinical 
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parameters. CRP gene analysis of all 430 patients could have helped to understand better 
individual variation in clinical course of SAB. In univariate analysis, lack of CRP decline in 
one or two weeks were predictive for fatal outcome. However, in final multivariate-
adjusted analysis, they appeared to be non-significant. In multivariate analysis, number of 
patients was relatively small, which may have influenced the result. In an individual level, 
lack of decline of CRP might still bear some importance as a warning signal but it cannot be 
used as a sign of deep infection focus.  
In predicting the presence of deep infection focus, CRP was diagnostic in adjusted analysis 
starting from the day of positive blood culture. Day seven WBC count was predictive of 
deep infection in univariate analysis, but was not significant in adjusted multivariate 
analysis. Serological tests, teichoic acid antibody (TAA) assay and ASTA are among the 
oldest and most frequently used tests in clinical practice to distinguish complicated from 
uncomplicated SAB [419,420], but low specificity limits their use [423,425]. TAA and ASTA 
were observed to be not prognostic in SAB [111]. ESR has good sensitivity but low specificity 
in diagnosing a deep infection focus [295,460]. Other markers for diagnosing a deep 
infection focus specifically in SAB are not well characterised. PCT was reported to be useful 
in diagnosing infection in general [401]. PTX3 is nonspecific marker of inflammation with 
low diagnostic value for sepsis [396]. As a marker of infection in febrile patients, cf-DNA 
was equally good as PCT but better than CRP in diagnosing an infection in patients with 
fever of unknown origin, localized infection and sepsis or septic shock [416]. Apoptosis 
markers were not able to distinguish patients who had fatal outcome, although they 
appeared predictive for high SOFA score in bacteraemia study [395]. 
6.3. Genetic polymorphism of the CRP gene and CRP level in Staphylococcus 
aureus bacteraemia  
We analysed the associations between six CRP gene SNPs with CRP levels in 145 SAB 
patients during the acute phase of disease. CRP gene SNPs have been shown to 
independently influence variations in basal CRP levels [332] However, studies on CRP gene 
SNPs associations with CRP levels in SAB or in any other infectious disease are not available. 
We observed that the A-minor allele rs3091244 in the CRP gene promoter region is 
associated with a higher maximal CRP level during the first week of SAB. However, this 
minor allele had no effect on CRP levels on the day of the positive blood culture or on day 
seven. This finding is in contradiction with the finding of the Study II. In Study II, mean CRP 
levels were at the highest level on the day of the positive blood culture and declined 
thereafter (in 430 SAB patients). Whereas in Study III, in 12 patients with the A-minor allele 
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of rs3091244 allele, maximal CRP response was recorded later, few days after day one. CRP 
levels in the beginning of the SAB may have more variable elements than maximal CRP 
during the first week. Severity of illness in patients may vary at the moment the blood 
culture is collected, and CRP in these patients may reach maximum levels few days after 
day one. However, no associations were detected in analyses of predisposing factors, 
underlying diseases and clinical manifestations with data comprising all CRP gene SNPs. In 
our study, CRP gene SNP partly determined maximal CRP levels in SAB. This genetic 
determination of higher maximal CRP suggests that extremely high CRP levels in individual 
patient should be interpreted with caution. Our finding partly explains why extremely high 
CRP is not necessarily prognostic for mortality or for the presence of deep infection. 
A deep infection focus was significantly associated with higher CRP levels and in 
multivariate analysis both A-minor allele rs3091244 and verified a deep infection focus 
determined the maximal CRP level during the first week. Factors which might have had 
influence on maximal CRP: age, gender, body mass index, surgical intervention and 
intravenous drug abuse were included but found non-significant in adjusted analysis. 
However, limitation of this analysis may have been the relatively small number of patients, 
and that severity of illness was not included.  
None of the studied CRP gene SNPs had an effect on mortality. Consistent with our findings, 
CRP gene SNPs were associated only with elevated basal CRP levels but had no association 
with increased mortality [461]. In contrast to our study, SNP rs2794521 was associated with 
increased mortality due to S. pneumonia bacteraemia but not due to bacteraemia caused 
by E. coli or α-haemolytic streptococci [47].  The only other study on CRP gene SNPs in 
infectious diseases observed a reduced risk (HR 0.5; 95% CI 0.3-0.9) of incident pneumonia 
but higher CRP level with rs3093058 in black people [462]. 
A small number of patients may have influenced the results. In the original clinical drug 
research study [4] 1226 SAB patients were identified and 430 included. In our study, 145 
patients from HUCH were included and 12 were carriers of rs3091244 A-minor allele. 
Multivariate analysis of the relatively small number patients may have reduced the power 
of the analysis. However, use of FDR analysis may have improved the reliability of multiple 
comparisons. The use of clinical drug research patient material as such may have led to bias 
in the selection of patients. Patients may have been excluded due to recruitment problems 
among critically ill with rapid disease course and fatal outcome. 
In our study, the A-minor allele of rs3091244 partly determined maximal CRP levels in SAB 
and. This same minor allele was modestly associated with elevated basal CRP levels at the 
populational level [463], and in acute coronary syndrome patients [464]. Association of this 
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SNP minor allele with CRP response in subjects with metabolic syndrome has been shown 
[465], but this association is unlikely with diseases such as acute maculodegenerative 
disease [466] or stroke [467]. This minor allele is also not associated with risk of abdominal 
aortic aneurysm (AAA) or high CRP levels [468], however, this allele was later found to be 
related to the increased incidence of AAA among general population and to correlate with 
higher CRP levels and increased AAA diameter [344]. In breast cancer patients, the same A-
minor allele of rs3091244 is associated with higher basal CRP levels but not with increased 
risk for fatigue, which is a common symptom in breast cancer patients [338]. In ankylosing 
spondylitis, higher CRP levels are associated with rs3091244 A-allele in patients with low 
disease activity as compared to patients without this allele [340], and in another 
publication with elevated risk for ankylosing spondylitis [469].  
6.4. suPAR as a prognostic factor in Staphylococcus aureus bacteraemia  
suPAR levels were evaluated in SAB patients and they were significantly higher in patients 
with a fatal outcome than survivors in 30-day surveillance period. Day three, four and 10 
suPAR levels were higher in fatalities than in survivors, whereas suPAR levels in patients 
with a deep infection focus did not differ from those without a deep infection focus. In 
contrast to suPAR, CRP on day three was not prognostic for fatal outcome. suPAR and CRP 
levels were not evaluated on the positive blood culture day. However, in the entire 430 
SAB material (Study II), CRP levels on the positive blood culture day and on day three were 
evaluated, and found non-prognostic for mortality. Consistent with our study, high suPAR 
levels appeared to be prognostic for fatal outcome in other bacteraemia studies on 
Streptococcus (pneumonia and β-haemolytic) and E. coli [389,390]. In critically ill septic 
patients, low suPAR levels are a positive predictor of overall survival [391]. In our study, we 
observed that suPAR levels on day 10 could predict mortality, which is consistent with 
findings of suPAR being prognostic in serial measurements in septic ICU patients up to 10-
14 days [470,471].  
In our study, presence of a deep infection focus was not associated with elevated suPAR 
levels. Publications on suPAR and diagnosis of deep infection in SAB are not available. In 
Streptococcus pneumonia bacteraemia study, patients with deep infection were not 
included [389] and in a report on pneumonia and meningitis and use of suPAR, the impact 
of a deep infection focus on suPAR levels was not analysed [472]. Deep infection focus is 
very common in SAB (84% prevalence in our study), whereas mortality due to SAB is 
generally lower (about 20%) [159,207,284,458]. Our small pilot study suggests that suPAR 
might not be a suitable diagnostic marker for detecting a deep infection focus. As a 
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diagnostic marker for infection, however, suPAR is useful when measured simultaneously 
with PCT. This combination could improve the efficiency of sepsis diagnosis, and the 
combination of plasma suPAR and APACHE II score could lead to more accurate mortality 
prediction [473].  
Elevated suPAR levels are recognised as a marker of poor prognosis in HIV, tuberculosis, S. 
pneumonia bacteraemia and malaria [389,474-476]. In our study, suPAR >9.25 ng/mL was 
predictive of mortality in SAB with a specificity of 0.68 and sensitivity of 0.79. In HIV, suPAR 
>6 ng/ml is associated with high two-year mortality [477]. In tuberculosis, elevated suPAR 
levels associated with mortality, but the highest median levels reported were rather low 
3.17 ng/mL [475]. In malaria, the highest median levels were slightly higher (7.9 ng/mL). In 
S. pneumonia bacteraemia, even higher cut-off values (10-10.3 ng/mL) were prognostic 
[389,472]. In critically ill patients, in (ICU) sepsis and in ventilator associated pneumonia 
predictive cut-off value for 28-day mortality was >12.9 ng/mL [478]. In another ICU study, 
suPAR level >12 ng/mL independently predicted mortality and suPAR levels were shown to 
remain stable for 10 days within survivors and non-survivors [479].  
Although suPAR seems to predict mortality quite reliably in many kinds of infectious 
diseases, individual levels should be interpreted with caution. Even in our relatively small 
patient group, overlapping between groups of survivors and non-survivors was seen. This 
could be partly explained by the use of serum instead of plasma, since suPAR levels in 
serum are higher than in plasma, although suPAR concentrations in serum and plasma 
correlate well [480]. In addition, a number of ELISA methods to measure suPAR levels are 
available. Use of different ELISA methods in studies may partly explain differences in suPAR 
levels. One commonly used ELISA assay has been suPARnostic kit. This kit is validated to 
measure suPAR levels between 0.6 and 22 ng/mL. Whereas, another ELISA method can 
detect suPAR levels down to 15 pg/ml of suPAR [481]. In previous reports, suPAR levels in 
women are higher than men [52]. However, in our small study we could not detect any 
differences according to gender. Levels of suPAR increase with age [482] and we observed 
this in our analysis. In patients >65 years high suPAR levels (>9.25 ng/mL) were clearly more 
common compared to patients <65 years (Study IV, Table 3). Limitation of the Study IV was 
the small number of patients. In multivariate analysis number of covariates was limited due 
to insufficient number of patients. In addition, due to strong linkage, we could not 
determine the relationship between suPAR with age and fatal underlying diseases in the 
same multivariate analysis. 
suPAR could possibly be used in predicting risk for poor outcome in SAB. Certain high suPAR 
level could help to allocate more resources to SAB patient at the greatest risk of dying.  
Such cut-off value due in SAB could be 9.25 ng/ml. However, low suPAR levels should not 
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be interpreted as an impetus for a reduction in therapeutic intensity. CRP could help in 
clinical-decision making in SAB. CRP levels greater than 100 mg/L on days 1-4 four should 
lead to meticulous search, drainage and surgical treatment of deep infections and 
assessment of antibiotic therapy. CRP greater than 20 mg/L after two weeks of treatment 
should help raise clinical suspicion of deep infection at the latest. 
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7. SUMMARY AND CONCLUSIONS 
The effect of S. aureus on plg activation and prognostic factors in S. aureus bacteraemia 
can be summarised as follows:  
I An enhancing effect of both S. aureus bacterial cells and surface proteins on plg 
activation by SAK was discovered. In an analysis of S. aureus cell-surface proteins, 
threeplg-binding proteins were revealed as inosine 5´-monophosphate 
dehydrogenase, alpha-enolase and ribonucleotide reductase. In conclusion, we 
demonstrated that S. aureus enhanced plg activation by SAK. Furthermore, we 
could identify three previously unidentified tentative plg receptors of S. aureus 
 
II In 430 SAB patients, predictive values of CRP in identifying fatal outcome and 
deep infections were determined. On day four, CRP >103 mg/L and on day 14, 
CRP >61 mg/L and WBC count >8.6 x109/L appeared prognostic of 30-day 
mortality in adjusted multivariate analysis. On the day of the positive blood 
culture, CRP >108 mg/L and on day 14 CRP >22 mg/L predicted the presence of 
deep infection. Compared to WBC count, CRP levels were superior in predicting 
mortality and presence of deep infection in SAB. These precise cut-off values of 
CRP might help diagnose patients with the complicated SAB. 
 
III In 145 S. aureus bacteraemia patients, the effect of CRP gene SNP on CRP levels in 
SAB was identified. The SNP rs3091244 A-minor allele was found to be a significant 
predictor of maximal CRP level in SAB. CRP gene SNPs were not associated with 
predisposing factors, underlying diseases, clinical outcomes, presence of deep 
infection or with the CRP levels at the time of the positive blood culture or one 
week after that. Together with a deep infection focus, carriage of the rs3091244 A-
minor allele carriage was found to determine the maximal CRP during the acute 
phase in SAB.  
 
IV The prognostic value of suPAR in 66 Staphylococcus aureus bacteraemia patients 
was identified. Day three suPAR levels >9.25 ng/mL predicted fatal outcome, and 
the difference in suPAR levels was observed up to 10 days after the onset of the 
disease. suPAR appeared not to be helpful in raising a suspicion of a deep infection. 
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